

UC Riverside

UC Riverside Previously Published Works

Title

Exposure, Retention, Exhalation, Symptoms, and Environmental Accumulation of Chemicals During JUUL Vaping

Permalink

<https://escholarship.org/uc/item/2q71h47v>

Journal

Chemical Research in Toxicology, 36(3)

Authors

Hua, My

Luo, Wentai

Khachatourian, Careen

et al.

Publication Date

2023-03-20

Data Availability

The data associated with this publication are within the manuscript.


Peer reviewed

**Exposure, Retention, Exhalation, Symptoms, and
Environmental Accumulation of Chemicals During JUUL™
Vaping**

Journal:	
Manuscript ID	
Manuscript Type:	
Date Submitted by the Author:	
Complete List of Authors:	Hua, My; University of California Riverside, Environmental Toxicology Graduate Program Luo, Wentai; Portland State University, Department of Civil and Environmental Engineering Khachatoorian, Careen; University of California Riverside McWhirter, Kevin; Portland State University, Civil and Environmental Engineering Leung, Sara; University of California Riverside Martinez, Teresa; University of California Riverside Talbot, Prue; University of California Riverside, Department of Molecular, Cell, and Systems Biology



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



1
2
3 **Exposure, Retention, Exhalation, Symptoms, and Environmental Accumulation of**
4 **Chemicals During JUUL™ Vaping**
5

6
7
8 My Hua^{†,‡}, Wentai Luo[§], Careen Khachatoorian[‡], Kevin J. McWhirter[§], Sara Leung[‡], Teresa
9
10 Martinez[‡], and Prue Talbot^{*†,‡}

11
12
13 [†]Environmental Toxicology Graduate Program University of California, Riverside, Riverside, CA,
14
15 92521, United States,

16
17
18 [‡]Department of Molecular, Cell and Systems Biology, University of California, Riverside,
19
20 Riverside, CA, 92521, United States,

21
22
23 [§]Department of Civil and Environmental Engineering, Portland State University, Portland, OR,
24
25 97201, United States

26
27
28 **Address correspondence to:** Prue Talbot, Department of Molecular, Cell and Systems
29
30 Biology, University of California, Riverside, 600 University Dr. Riverside, CA 92521, USA


31
32 **Telephone:** 951-827-3768.

33
34
35 **E-mail:** talbot@ucr.edu
36
37

38
39
40 **Word count:** 7,912
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



For TOC Only



ABSTRACT

Little is known about the chemical exposures that electronic cigarette (EC) users receive and emit during JUUL™ vaping and if exposures produce symptoms dose dependently. This study examined chemical exposure (dose), retention, symptoms during vaping, and the environmental accumulation of exhaled propylene glycol (PG), glycerol (G), nicotine, and menthol in a cohort of human participants who vaped JUUL™ “Menthol” ECs. We refer to this environmental accumulation as “EC exhaled aerosol residue” (ECEAR). Chemicals were quantified using gas chromatography/mass spectrometry in JUUL™ pods before and after use, lab-generated aerosols, human exhaled aerosols, and in ECEAR. Unvaped JUUL™ “Menthol” pods contained ~621.3 mg/mL of G, ~264.9 mg/mL of PG, ~59.3 mg/mL of nicotine, ~13.3 mg/mL of menthol, and ~0.1 mg/mL of the coolant WS-23. Eleven experienced male EC users (aged 21-26) provided exhaled aerosol and residue samples before and after vaping JUUL™ pods. Participants vaped *ad libitum* for 20 minutes, while their average puff count (22 ± 6.4) and puff duration (4.4 ± 2.0) were recorded. The transfer efficiency of nicotine, menthol, and WS-23 from the pod fluid into the aerosol varied with each chemical and was generally similar across flow rates (9 - 47 mL/sec). At 21 mL/sec, the average mass of each chemical retained by the participants who vaped 20 minutes was 53.2 ± 39.3 mg for G, 14.0 ± 18.9 mg for PG, 3.3 ± 2.6 mg for nicotine, and 0.5 ± 0.4 mg for menthol, with retention deduced to be ~90% - 100% for each chemical. There was a significant positive relationship between the number of symptoms during vaping and total chemical mass retained. ECEAR accumulated on enclosed surfaces where it could contribute to passive exposure. These data will be valuable to researchers studying human exposure to EC aerosols and agencies that regulate EC products.

Abstract Word Count: 297



INTRODUCTION

Electronic cigarettes (ECs) have been used for over 10 years in the United States, during which time they have evolved rapidly into sophisticated devices capable of delivering nicotine and other chemicals to users. JUUL™ products belong to the fourth generation of ECs^{1, 2} and have been one of the largest selling nicotine vape products in the United States³. In 2018, JUUL™ took most of their flavored products off the market after public and government concern over their popularity with high school students and young adults⁴⁻⁶. Then, in July 2020, JUUL™ discontinued sales of its “Classic Tobacco” pods, leaving only “Virginia Tobacco” and “Menthol” flavors available to consumers. In the same year, the Food and Drug Administration (FDA) issued an enforcement policy to remove cartridge-based ECs (except for menthol and tobacco flavors) from the market⁷. More recently, in June 2022, the FDA denied JUUL™ authorization to market its products citing lack of sufficient toxicological evidence, but the company appealed the decision and has since been allowed to continue sales⁸. Despite the FDA’s flavor enforcement policy and attempts to regulate EC flavors, JUUL™ “Menthol” products are still readily available and popular both online and in stores.

The dominant chemicals in JUUL™ “Menthol” pods are nicotine (~30 or 60 mg/mL), a solvent comprised of glycerol (G) and propylene glycol (PG) (70:30 ratio), menthol (~13 mg/mL), and benzoic acid (~44.8 mg/mL)⁹⁻¹². These concentrations are higher than normally used in consumer products⁹, which has raised concerns about their effects on human health.

This concern is supported by cell, animal, and human studies on JUUL™ ECs. In vitro, JUUL™ e-liquids and dissolved aerosols were cytotoxic to numerous human cell types^{9,13-17}, an effect that was correlated with nicotine and menthol concentrations in BEAS-2B cells⁹. In Calu-3 and HEK293T cells, JUUL™ “Menthol” and “Mint” pods increased intracellular Ca²⁺^{14,16}, the

1
2
3 proinflammatory cytokine IL-6, and Annexin V, an early apoptotic marker, with responses being
4 more pronounced in “Mint”¹⁶. JUUL™ “Mint” aerosols also upregulated genes involved in ROS
5 production, lipid peroxidation, and carcinogen metabolism, while downregulating genes related
6 to cytokine and chemokine signaling in type-2 alveolar epithelial cells¹⁸. Air liquid interface
7 exposure to JUUL™ “Glacier Mint” aerosols increased cell death and tissue inflammation in
8 human oral epithelium¹⁹. Menthol can be toxic at high doses in vitro and triggered inflammatory
9 pathways¹⁵. Exposure to JUUL™ “Menthol” aerosols resulted in an immediate increase in proton
10 leak and decreased coupling efficiency, as well as a decrease in complex I, II, and IV, causing
11 mitochondrial dysfunction in lung epithelial cells¹⁷.

12
13
14 In rodent studies, JUUL™ aerosols produced adverse effects on the vascular, immune,
15 and reproductive systems. In rats, various JUUL™ flavors, including “Menthol”, impaired
16 endothelial function^{20,21}. In mice, JUUL™ “Menthol” aerosols (2 weeks, 70 puffs/daily) caused
17 hyperactivation of platelets and shortened thrombus occlusion and bleeding times²², while 2
18 weeks of JUUL™ aerosol exposure to a higher dose (192 puffs/day, flavor not reported)
19 disrupted the blood brain barrier, resulting in ischemic stroke²³. In mice, JUUL™ aerosols also
20 increased inflammation and altered plasma and urinary metabolites, which could increase
21 disease risk²⁴⁻²⁵. JUUL™ “Mango” and “Mint” aerosols induced inflammation of the brain, lungs,
22 heart, and colon²⁴, and JUUL™ “Mint” significantly increased lung neutrophils and oxidative
23 stress²⁶. Exposure of pregnant BALB/c mice to JUUL™ “Mint” aerosol for 1 hour/day x 20 days²⁷
24 upregulated genes associated with hypoxia and oxidative stress in the uterus and placenta,
25 while body weights and lengths of the offspring decreased²⁷.

26
27
28 Human studies have reported on health effects, nicotine dependence, and blood
29 pressure changes associated with JUUL™ use. Symptoms related to the respiratory,
30 neurologic, and cardiovascular systems have been reported on Reddit and Twitter by EC users
31 vaping various JUUL™ products²⁸⁻²⁹. JUUL™ “Menthol” was associated specifically with throat
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 issues (e.g., burning, harshness, and throat hit) on Twitter²⁸. In a survey, participants using
4
5 JUUL™ ECs for the first-time experienced burning in the throat, coughing, wheezing, and
6
7 headache³⁰. Immediately after vaping JUUL™ “Menthol”/“Mint” or “Classic Tobacco”,
8
9 participants reported nausea and dizziness³¹. Additionally, 40.1% of JUUL™ adolescent users
10
11 who vaped in the past 30 days were likely to have nicotine dependence symptoms (e.g.,
12
13 cravings)³². JUUL™ vaping also increased blood pressure and mean arterial pressure in human
14
15 users³³. Vaping a ratio of 50/50 PG/G in 30 never-smokers showed that the solvents caused
16
17 lung inflammation significantly correlated with change in cell counts (cell concentrations,
18
19 macrophages, and lymphocytes) and cytokines (IL-8, IL-13, and TNF α) in bronchoalveolar
20
21 lavage samples³⁴.
22

23
24
25 EC users exhale clouds of aerosol (which we refer to as “exhale”) that settle on indoor
26
27 surfaces forming “EC exhaled aerosol residue” (ECEAR)³⁵⁻³⁶, which could passively expose
28
29 non-vapers to EC chemicals. ECEAR generated using “Dewberry Cream” and “Churrios” in tank
30
31 style ECs contained nicotine, nicotine alkaloids, tobacco specific nitrosamines (TSNAs), and
32
33 flavor chemicals³⁵. ECEAR derived from “Churrios” e-liquid induced IL-1 α secretion following air
34
35 liquid interface exposure of EpiDerm™ tissue, a 3D human skin model³⁷. Some ECEAR
36
37 chemicals caused oxidative damage and inflammation to human skin³⁷. No data have previously
38
39 been reported on ECEAR associated with JUUL™ products.
40

41
42 Various lines of evidence show that JUUL™ e-liquids and aerosols can produce adverse
43
44 effects in cells, animals, and humans and that exhaled aerosols have the potential to passively
45
46 expose non-vapers to EC chemicals. However, little is known about the actual chemical
47
48 exposures that humans vaping JUUL™ ECs receive, how doses relate to symptoms, if users
49
50 experience adverse symptoms during vaping, and if non-vapers are at risk. The purpose of this
51
52 study was to characterize the exposure to and retention of flavor chemicals, solvents, and
53
54 nicotine in JUUL™ “Menthol” users, evaluate the residues deposited by exhaled aerosols, and
55
56
57
58
59
60


1
2
3 correlate the frequency of symptoms reported during JUUL™ vaping to the calculated dose
4 received. JUUL™ “Menthol” was used because it is popular, readily available, and can
5
6 substitute for JUUL™ “Mint” products, which are no longer marketed. A cohort of male JUUL™
7 EC users provided exhale and ECEAR samples after vaping JUUL™ “Menthol”. Topography
8 (puff duration and total puffs seconds) was evaluated for each user. The solvents (PG and G),
9
10 nicotine, menthol, and flavor chemicals were quantified in the exhale and ECEAR after a 20-
11
12 minute vaping session. Data on acute symptoms were collected before, during, and after
13
14 vaping, and correlated with mass retained for the dominant chemicals. This is the first
15
16 comprehensive study on JUUL™ “Menthol” that includes data on topography, exposure,
17
18 retention, self-reported symptoms and their frequency before, during, and after vaping. These
19
20 data will be important in future studies that evaluate human health effects caused by JUUL™
21
22 vaping and in designing experiments with relevant exposures to the chemicals in JUUL™
23
24 products. Supplementary Table 1 introduces abbreviations and terms used in this study.
25
26
27
28
29

30 31 **METHODS**

32 33 ***Recruitment of Human Subjects***

34
35 An advertisement for participants was placed in the University of California, Riverside listserv.
36
37 The study inclusion criteria were: (1) at least 6 months of JUUL™ use, (2) ability to use JUUL™
38
39 “Menthol” containing 5% (50 mg/mL) of nicotine, (3) 21 years or older, (4) lung inhalers (users who
40
41 take aerosol into their lungs not just their mouth)³⁸, and (5) no pre-existing health conditions. The
42
43 exclusion criteria were: (1) insufficient experience using JUUL™ products, (2) less than 21 years of
44
45 age, (3) inability to use nicotine products with 50 mg/mL of nicotine, (4) mouth inhalers (those who
46
47 inhale only into the mouth)³⁸, and (5) individuals with pre-existing conditions.
48
49
50

51
52 Interested volunteers were directed to an online Qualtrics survey that asked questions
53
54 covering study eligibility and tobacco product use. Participants were screened based on their
55
56 responses to the questions. Participants that specified EC and minimal tobacco and substance use
57
58
59
60



1
2
3 were preferred. Selected volunteers were asked to come into the lab to review and sign informed
4 consent forms, approved by the UCR Human Research Review Board, and agree to study protocols
5 and vape product use. Participants had their initial puffing topography recorded to assess whether
6 they inhaled into the mouth only or inhaled into their lungs.
7
8
9

10
11 Control participants who did not use ECs or tobacco cigarettes, who were at least 18 years
12 old, and had no pre-existing health conditions were also recruited from the University. The controls
13 came on separate days from the EC users to provide exhale samples.
14
15
16

17 ***Purchase of JUUL™ Products***

18
19 JUUL™ “Menthol” pods (5.0% nicotine) and batteries were purchased from local convenience
20 stores in Riverside, CA and used within 2-3 months. To avoid possible use of counterfeit ECs³⁹,
21 products were authenticated by contacting JUUL™ to confirm the batch numbers on the products.
22
23 Vaped pods were stored at room temperature in 50 mL conical tubes until shipped to Portland State
24 University for fluid analysis.
25
26
27
28
29
30

31 ***Study Design***

32
33 Exhale and ECEAR samples were collected from participants before and after vaping for 20
34 minutes on two separate days (Day 1 and Day 2) (Supplementary Figure 1). Before coming into the
35 lab, participants were asked to abstain from vaping, other tobacco products, recreational drugs,
36 alcohol, and caffeine for at least 10 hours before the study. When participants arrived, they were
37 asked to rinse their mouths thoroughly with water for at least 30 seconds. Participants were given
38 fresh JUUL™ “Menthol” pods to use during the two study days, along with a fully charged JUUL™
39 battery. JUUL™ “Menthol” pods were weighed before and after vaping. Controls provided a single
40 exhale sample during one session while breathing room air.
41
42
43
44
45
46
47
48
49

50 ***ECEAR Collection from Control and JUUL™ Participants (Day 1)***

51
52 On Day 1, participants vaped for 20 minutes *ad libitum*, and the exhaled aerosol was allowed
53 to settle for 30 minutes before collection and subsequent extraction. Puff duration, which was
54 measured using a stopwatch, was defined as the interval between activation of the light on the
55
56
57
58
59
60

1
2
3 JUUL™ and removal of the EC from the participants' mouth. Puff count was recorded manually by
4 researchers. On Day 2, participants were asked to take the same number of puffs. To collect the
5 ECEAR, a paper towel was placed on the bottom of a 3 cubic foot acrylic box with a detachable top.
6 Boxes had 1 cm holes on each side to allow aeration. After each puff, participants exhaled into a
7 three-foot Tygon tube to deposit aerosol in the tank. After each session, there was a 30-minute waiting
8 period before the paper towels were collected and placed into Ziploc bags for immediate extraction.
9 Tubing for each participant was washed with water, ethanol, water, followed by ethanol, water,
10 ethanol, followed by water only and then dried overnight.

11
12 Paper towels with ECEAR were cut into small pieces (1.3 x 1.4 inches) and soaked in IPA
13 (isopropyl alcohol) (0.1 g of paper towel/mL of IPA) for an hour. The tubing was washed with IPA and
14 combined with paper towel extracts, put into 1 ml GC/MS vials, and shipped to Portland State
15 University for GC/MS flavor chemical analysis.

16
17 The total surface area of the acrylic box and paper towel that the ECEAR was collected on
18 was determined. The ECEAR concentration measured in the paper towel cut out was multiplied by
19 the total surface area of the acrylic box to obtain an estimate of the total mass (mg) of ECEAR
20 deposited. Previous lab experiments showed that ECEAR collected in the lab-made acrylic box was
21 fairly evenly distributed (not shown).

22 ***Exhale Collection (Day 2)***

23
24 On Day 2, participants returned to the lab, and pre and post vape exhale samples were
25 collected. Two impingers in tandem, each with 25 mL of IPA, were used to capture participants'
26 exhale, as previously described³⁸. Participants exhaled into a 1-foot Tygon tube that connected to the
27 first impinger. Control (from the non-EC users) and pre-vape exhale was deposited directly into the
28 impinger without vaping. Participants were given signals during the pre and post vape session so
29 that they exhaled the same number of times as they puffed on Day 1. Controls were asked to provide
30 one exhale sample/minute during a 20-minute session.

31 ***JUUL™ Aerosol Production at Various Flow Rates***



1
2
3 Triplicate JUUL™ “Menthol” aerosol samples were generated in the lab at various flow
4 rates (9, 11, 13, 21, 41, and 47 mL/sec) for 20 minutes (1 puff/minute at 4.3 seconds/puff), as
5 described in previous methods⁴⁰⁻⁴¹. To collect the aerosols, two glass impingers were connected
6 in tandem and attached to a peristaltic pump. A smoking machine⁴² was used to count and time
7 the puffs, and generate aerosols, as described in detail previously⁴¹. Based on prior data⁴⁰, a
8 4.3 second puff was taken every minute. Pods were weighed before and after vaping sessions.
9 Based on prior data⁴³, a range of flow rates was selected for transfer efficiency calculations.
10
11
12
13
14
15
16
17

18
19 ***Identification and Quantification of Nicotine, Flavor Chemicals, and Solvents in Samples***
20
21 ***Using GC/MS***
22

23
24 The nicotine and flavor chemical concentrations in pod e-liquids, exhale, and ECEAR
25 were analyzed by GC/MS at Portland State University. Internal standard-based calibration
26 procedures similar to those described elsewhere were used^{9,44}, and analyses for nicotine and
27 180 flavor-related target analytes were performed with an Agilent 7693 autosampler (Santa
28 Clara, California, USA), Agilent 7890A GC and Agilent 5975C MS. The capillary column used
29 was Rxi-624Sil MS (30 m × 250 μm × 1.4 μm film thickness). The relatively high film thickness
30 was chosen to provide the column with adequate capacity for compounds present at high
31 concentrations and retention for relatively volatile flavor compounds. For each e-liquid sample,
32 50 μL was dissolved in 950 μL of isopropanol (Fisher Scientific, Fair Lawn, New Jersey, USA).
33 20 μL of internal standard solution (2 μg/μL of 1,2,3-trichlorobenzene in isopropyl alcohol) was
34 added into 1 mL of diluted refill, exhale, and ECEAR extract samples before analysis; 1 μL was
35 injected into the GC/MS at 235 °C with a 10:1 split. The GC temperature program was: 40 °C
36 hold for 2 min; 10 °C/min to 100 °C; then 12 °C/min to 280 °C and hold at 280 °C for 8 min, then
37 10 °C/min to 220 °C. The MS was operated in electron impact (EI) ionization mode (70eV) and
38 positive ion detection mode. The ion source temperature was 220°C and the quadrupole
39 temperature was 150°C. The scan range was from 34 to 400 amu. Each target analyte was
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 quantitated using: (a) authentic standard material; (b) its specific quantitation ion; and (c)
4
5 internal-standard (1,2,3-trichlorobenzene)-normalized multipoint calibration based on peak area.
6
7 When the concentrations were less than the limit of quantitation, they were estimated based on
8
9 the response factor generated from the calibration standards.
10

11
12 To estimate the PG and G concentration in all samples previously analyzed for flavor
13
14 chemicals, an external standard calibration curve was applied. PG and G concentrations often
15
16 overloaded the MS during analysis and thus are likely underestimated at high sample
17
18 concentrations.
19

20
21 Control air samples collected from the fume hood and IPA rinses of the Tygon tubing
22
23 were collected and analyzed by GC/MS to confirm that chemicals did not come from these
24
25 sources.
26

27 28 29 ***Calculating Transfer Efficiency for Nicotine, Menthol, and Solvents (PG and G) at Various*** 30 31 ***Flow Rates*** 32

33
34 The transfer efficiency is the percent of the chemical in the pod liquid that transfers to
35
36 the aerosol during vaping. To calculate the transfer efficiency at our six flow rates, the aerosol
37
38 concentration of the chemical ($\mu\text{g/g}$) was multiplied by the pod liquid density (g/mL) and divided
39
40 by the total concentration ($\mu\text{g/mL}$) of the chemical in the pod liquid before aerosolization. The
41
42 percent transfer was calculated by multiplying this result by 100%.
43
44

$$45
46 \text{\% Transfer Efficiency} = \frac{\text{aerosol concentration of the chemical} \times \text{pod fluid density}}{\text{total concentration of chemical in pod fluid}} \times 100\%
47
48
49$$

50 51 ***Calculating Mass Transfer Derived from Transfer Efficiency Data*** 52

53
54 The mass of chemical (nicotine, menthol, PG, and G) that transferred from pod fluid to
55
56 aerosol was calculated at six flow rates. The mass that transferred to the aerosol was calculated
57
58
59
60

1
2
3 by multiplying the concentration of the chemical in the aerosol (ng/mL) by the total volume of
4
5 IPA it was captured in (mL). The mass that transferred to the aerosol was converted to mg by
6
7 dividing by 10⁶. The average and standard deviation for the mass consumed during the vaping
8
9 session was determined.
10

11
12 To confirm that the mass transfer was calculated correctly, it needed to be in agreement
13
14 with the percent transfer efficiency. The total chemical consumed during vaping was calculated
15
16 by multiplying the unvaped chemical concentration (mg/mL) by total weight (g) divided by the
17
18 density of the pod fluid (mg/uL = g/mL). The total chemical consumed was converted to mg by
19
20 dividing by 1000. The mass transfer was divided by the total chemical consumed during vaping
21
22 multiplied by 100%. This percent value was compared to our transfer efficiency to confirm that
23
24 the numbers matched and that the mass transfer was accurate.
25
26

27
28
29
$$\text{Mass Transfer (mg)} = \frac{\text{total mass chemical quantified} \times \text{total IPA volume}}{\text{conversion factor (depending on units for mass)}}$$

30
31

32
33 ***Calculating Exposure, Mass Retained, and Percent Retention of Nicotine,***
34
35 ***Menthol, and Solvents in JUUL™ Users***
36

37
38 The maximal exposure to nicotine, menthol, PG, and G was calculated for each vaped
39
40 pod by determining the total pod liquid (mL) consumed multiplied by the concentration (µg/mL)
41
42 of the chemical. To calculate the actual exposure for each chemical, the maximal exposure was
43
44 multiplied by the transfer efficiency (%) for each chemical. To determine the mass retained (mg)
45
46 for each chemical, the mass of each chemical in the exhale was subtracted from the actual
47
48 exposure. To calculate the percent retention, the mass retained was divided by the actual
49
50 exposure and multiplied by 100%.
51
52

53
54 ***Exposure Estimates for a Single Puff, a Session, and a Whole Day***
55
56
57
58
59
60



1
2
3 Using the mass retention data for a single session for the dominant JUUL™ chemicals,
4 we estimated how much users retained in a single puff and whole day. Single puff retention was
5
6 calculated by dividing the total retention in a session by the total number of puffs taken in the
7
8 session. For the whole day estimates we used the average number of puffs estimated for
9
10 human EC users (~140 puffs per day)⁴⁵. The nicotine equivalency to cigarette use was also
11
12 calculated for a single session (1 cigarette = 1.1 mg; whole pack = 22 mg)⁴⁶ and estimated for
13
14 the whole day.
15
16

17 18 19 ***Symptoms Reported by JUUL™ Users***

20
21 Surveys were administered to both JUUL™ users and controls. The surveys contained
22
23 questions on symptoms commonly reported by EC users. The surveys asked users to select
24
25 symptoms experienced before, during, and after their exhale session on Day 2. The results
26
27 were recorded, and the number of symptoms reported was correlated to the total mass retained
28
29 for the dominant JUUL™ “Menthol” chemicals calculated for the participants during vaping.
30
31

32 33 ***Statistical Analysis***

34
35 A one-way analysis of variance (ANOVA) was performed to analyze the difference
36
37 between the transfer efficiencies of nicotine, menthol, WS-23, PG, and G at various flow rates.
38
39 A correlation analysis was performed on the relationship between the transfer efficiency and
40
41 mass of the e-liquid consumed during aerosolization.
42
43

44
45 For symptom data, an outlier analysis was performed for each user. The ROUT method
46
47 on GraphPad Prism was used to detect outliers while fitting a curve with nonlinear regression.
48
49 This outlier detection method is based on the false discovery rate, to decide which points
50
51 are far enough from the prediction of the model to be called outliers. Following the
52
53 identification of an outlier, a correlation analysis and significance testing was performed on the
54
55
56
57
58
59
60

1
2
3 symptoms and chemical mass retained data for each user (except LO who was determined to
4 be an outlier) to understand the dose response relationship. All statistical analyses were done
5
6 using GraphPad Prism (GraphPad, San Diego).
7
8
9

10 **RESULTS**

11 ***Demographics of Recruited Participants***

12
13
14
15
16
17 Eleven male participants with at least 6 months experience using JUUL™ products were
18 recruited from the University listserv. The participants included the following ethnicities:
19 Asian/Asian-American and Pacific Islander (N = 6), African American (N = 2), Middle Eastern (N
20 = 1), Hispanic (N = 1), and White/Caucasian (N = 1). Three of these participants identified as
21 mixed race. Three participants started smoking cigarettes socially after using EC products.
22
23
24
25
26 Three other participants were previous smokers. The age of the users ranged from 21 to 26
27 years. Some of the participants reported occasional use of tetrahydrocannabinol (N = 6), alcohol
28 (N = 5), and cocaine (N = 2).
29
30
31
32
33
34

35 The non-e-cigarette users (controls) included the following ethnicities: Asian-American
36 (N = 9), Hispanic (N = 1), and mixed race (N = 1). None of the controls were previous smokers
37 and reported no prior drug use. The age of the controls ranged from 18-34.
38
39
40
41

42 On the modified Fagerstrom Test⁴⁷, participants indicated that they used their EC
43 products 10-19 session/day. The average nicotine dependence was 4 using the Fagerstrom
44 index, which indicates a low to moderate level of addiction.
45
46
47
48

49 ***Chemical Composition of JUUL™ Menthol Pods***

50
51 JUUL™ "Menthol" pods contain four dominant chemicals, which were detected at
52 concentrations above 1 mg/mL (Supplementary Figure 2A, B). The average concentrations of
53 the four chemicals quantified from three unvaped pods were: nicotine ~59 mg/mL, menthol ~13
54
55
56
57
58
59
60

1
2
3 mg/mL, PG ~265 mg/mL, and G ~621 mg/mL. The relative abundance of each chemical was:
4
5 solvents > 91%, nicotine 6%, and menthol 1% (Supplementary Figure 2B). This figure does not
6
7 take into account benzoic acid, which was not measured in this study.
8
9

10 ***Total Mass of Pod Liquid Consumed During Vaping Sessions***

11
12 The total mass of the JUUL™ “Menthol” pod liquid consumed during the vaping sessions
13 was recorded for all participants in Days 1 and 2 (Supplementary Figure 3). The mass of the
14 consumed liquids ranged from 10 to 180 mg. The average mass consumed was 73.6 ± 34.1 mg
15 for Day 1 and 70.9 ± 53.6 mg for Day 2, and these means were not significantly different ($p =$
16 0.78). Most users consumed more than 40 mg during the vaping sessions, and three consumed
17 more than 100 mg.
18
19
20
21
22
23

24 ***Flavor Chemicals in JUUL™ “Menthol” Pod Fluid that were ≤ 1 mg/mL***

25
26 GC-MS analysis identified 19 flavor chemicals in two unvaped JUUL™ “Menthol” pods
27 and in the vaped pods from all participants (Supplementary Table 2). Of the 19, eight were
28 above the limit of quantification (LOQ) ($10 \mu\text{g/mL}$), but < 1 mg/mL (WS-23, benzyl alcohol,
29 hydroxyacetone, caffeine, p-menthone, β -damascone, neomenthol, and isopulegol). The
30 concentrations of WS-23, benzyl alcohol, and hydroxyacetone were similar in fluids before and
31 after vaping. The concentrations of the other chemicals decreased after vaping.
32
33
34
35
36
37
38
39
40

41 ***Puff Duration, Puff Number, and Total Puffs Seconds for JUUL™ Users***

42
43 The total number of puffs and average puff duration were recorded for each participant
44 during Day 1 (ECEAR) and Day 2 (Exhale) sessions (Supplementary Figure 4A). The total puff
45 number ranged from 11-36 for both days (Supplementary Figure 4A) and averaged 22 ± 6.4 .
46
47 Participants were asked to puff the JUUL™ for the same number of puffs during the Day 2
48 session. Puff duration for each individual was similar from day to day and averaged 4.1 ± 1.6
49 seconds on Day 1 and 4.7 ± 2.1 seconds on Day 2, which is in good agreement with prior
50
51
52
53
54
55
56
57
58
59
60

1
2
3 topography studies^{40,48-49}. The insert in Supplementary Figure 4A shows the puff duration and
4 puff number for one individual (JE) who provided data on three separate occasions. Puff
5
6 duration did not differ significantly ($p > 0.05$) across the three days (Supplementary Figure 4A
7
8 insert),
9

10
11 The total puff seconds (TPS) (puff duration in seconds times total puff number) was
12 calculated for each participant during each session (Supplementary Figure 4B). The TPS gives
13 a quantitative measure of how much each user vaped during one session. As can be seen in
14
15 Supplementary Figure 4B, TPS varied considerably among participants. For Day 1 (ECEAR)
16
17 and Day 2 (Exhale), the TPS ranged from ~19 - 135 and from ~12 - 188, respectively. The
18
19 average TPS for both days was $\sim 93.3 \pm 33.7$ seconds. Except for one individual (BO), who had
20
21 a puff duration that was difficult to evaluate, TPS values for any given individual were similar on
22
23 Days 1 and 2.
24
25
26
27
28

29 ***Transfer Efficiency and Mass Transfer of Nicotine, Menthol, WS-23, and Solvents at*** 30 31 ***Various Flow Rates*** 32

33
34 For each dominant chemical as well as WS-23, the transfer efficiency (percent of a
35 chemical that transferred from the fluid to the aerosol) and the actual mass that transferred (mg)
36
37 are shown in Figure 1 for various flow rates. The transfer efficiency (percent) of nicotine,
38
39 menthol, WS-23, PG, and G was determined for aerosols generated in our lab on a smoking
40
41 machine at flow rates between 9-47 mL/sec (Figure 1 A-F) and statistical analyses were
42
43 performed on the percent transfer efficiency data. The percent transfer efficiency was affected
44
45 by flow rate. At flow rates of 9 mL/sec, there were no statistically significant differences between
46
47 chemicals in percent transfer efficiency (Figure 1A). As flow rates increased, significant
48
49 differences in the transfer efficiencies of individual chemicals were observed (Figure 1 B-F). At
50
51 flow rates of 41 and 47 mL/sec, the transfer efficiencies were significantly different for each
52
53
54
55
56
57
58
59
60

1
2
3 chemical (Figure 1 E,F). Specifically, PG and G transferred the most efficiently (~100%),
4
5 followed by nicotine (~73%), menthol (~58%), and WS-23 (~45%) (Figure 1F).
6

7
8 The mass (mg) of each chemical that transferred into the aerosol is shown in the colored
9
10 bars in Figure 1A-F for each flow rate. In general, the mass that transferred varied for each
11
12 chemical (at 47 mL/sec the average masses were G = 62.7 mg; PG = 26.2 mg; nicotine = 4.2
13
14 mg; menthol = 0.7 mg; WS-23 = 0.004 mg). These data show the actual mass of each chemical
15
16 that a user would inhale at different flow rates. In general, mass increased when transfer
17
18 efficiency and flow rate increased, except at 41 mL/sec when a decrease in mass was observed
19
20 (Figure 1E). This decrease may be due to an unidentified technical variation, such as greater
21
22 loss of aerosol chemicals in the tubing and capture system in this experiment.
23

24
25 The effect of flow rate on transfer efficiency of each chemical was also examined (Figure
26
27 2). The flow rate did not affect the percent transfer for nicotine, menthol, and WS-23, which
28
29 were not statistically significant across all flow rates ($p > 0.05$). However, for PG and G, the
30
31 transfer efficiency increased at the higher flow rates (e.g., PG = 55.5% at 9 mL/sec; PG =
32
33 101.9% at 47 mL/sec) (Figure 2D,E). The mass transferred at 41 mL/sec (e.g., PG = 15.5 mg)
34
35 was lower than the masses at 21 mL/sec (e.g., PG = 24.4 mg) and 47 mL/sec (e.g., PG = 26.2
36
37 mg), perhaps due to an unidentified technical variation in this experiment (Figure 2E).
38
39
40
41
42
43

44 ***Estimated Maximal and Actual Exposure for Each Dominant Chemical***

45
46 The maximal exposure to the dominant JUUL™ chemicals varied among the participants
47
48 and depended on the concentration of each chemical in the pod fluid and how much fluid was
49
50 consumed (Figure 3). For nicotine, the maximal exposure ranged from 0.6 – 10.9 mg, whereas
51
52 menthol ranged from 0.1 – 2.4 mg. The maximal exposure for PG and G ranged from 2.7 – 48.6
53
54
55
56
57
58
59
60

1
2
3 mg and 6.3 – 114 mg, respectively. The average maximal exposures in mg were 4.2 ± 3.2 for
4
5 nicotine, 0.95 ± 0.72 for menthol, 18.9 ± 14.31 for PG, and 44.3 ± 33.6 for G.
6
7

8 The actual exposure to the dominant JUUL™ chemicals considers the transfer efficiency
9 of each chemical. For nicotine, the actual exposure ranged from 0.4 – 8.7 mg, whereas menthol
10 ranged from 0.08 - 1.5 mg. The actual exposure for PG was the same as the maximal exposure
11 because its transfer efficiency was 100%. The actual exposure for G (7.6 – 137 mg) was slightly
12 greater than the maximal exposure. This could be explained by the fact the concentrations of G
13 were estimated, which may have produced transfer efficiencies that were greater than 100%..
14
15 The average actual exposures in mg were 3.4 ± 2.6 for nicotine, 0.6 ± 0.4 for menthol, $18.9 \pm$
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

***Nicotine, Menthol, Solvents, and Other Chemicals Detected in Participants' Exhale After
JUUL™ Vaping***

Nicotine, menthol, PG, and G were quantified in JUUL™ users' exhale samples (Figure 4 A,B). Data in Figures 7A and B show the total mass for each chemical captured in both impingers was <1 mg in all but one exhale sample. The total exhaled mass of nicotine after vaping ranged from 0 to ~1 mg (Figure 4A), whereas menthol ranged from 0 to 0.1 mg. Four patterns of exhale for nicotine and menthol were identified across the participants. Two users exhaled more nicotine than menthol; four users exhaled more menthol than nicotine; four users exhaled menthol only; and one did not exhale either menthol or nicotine. Control participants did not exhale nicotine or menthol, except for one participant who exhaled trace levels of nicotine.

Very little PG (0 to < 0.01 mg) and G (0 to 0.01 mg) were detected in the exhaled aerosol of JUUL™ users. In some cases, there was less solvent than nicotine or menthol in the exhale. None of these chemicals were found in exhale of the participants before vaping. All control exhale samples were negative for PG and G.

1
2
3 Other flavor chemicals detected in users' exhale included benzaldehyde, p-menthone,
4 acetophenone, and triacetin (Supplementary Figure 5A-C). Only one user had detectable p-
5 menthone in their post-vape exhale sample (not shown). Benzaldehyde was not detected in five
6 samples and was below the limit of quantification (500 ng/mL) in six samples. Triacetin and
7 acetophenone were detected in most pre-vape samples and were higher in concentration in
8 nine post-vape samples. The control participants were negative for p-menthone and triacetin.
9 Five controls had benzaldehyde in their exhale and most controls had detectable concentrations
10 of acetophenone that ranged from 0.0002 - 0.0003 mg and 0.0003 - 0.001 mg, respectively

11
12
13
14
15
16
17
18
19
20 ***Retention of Nicotine, Menthol, PG, and G by Study Participants Calculated at a Flow***
21 ***Rate of 21 mL/sec***
22

23
24
25 The total mass retained and the percent retention for nicotine, menthol, PG, and G were
26 calculated at six flow rates (9, 11, 13, 21, 41, and 47 mL/sec) for each user as described in the
27 Materials and Methods (Supplementary Table 3). For the 21 mL/sec flowrate, the mass retained
28 for each chemical was variable among participants and ranged from ~0.05 – 8.7 mg for nicotine,
29 ~0.05 – 1.4 mg for menthol, ~2.7 – 48.6 mg for PG, and ~7.6 – 136.7 mg for G (Figure 5
30 A,C,E,G).
31
32
33
34
35

36
37
38 At the 21 mL/sec flow rate, the percent retention for all users, excluding BL, ranged from
39 90-100% for nicotine and 86-100% for menthol (Figure 5 B,D). All users retained between 99-
40 100% of the PG and G. BL was not included in the nicotine and menthol ranges since he was
41 likely a mouth inhaler rather than a lung inhaler³⁸. The results for mass retained and percent
42 retention were similar for the low (9-13 mL/sec) and high (21-47mL/sec) flowrates
43 (Supplementary Table 3).
44
45
46
47
48
49

50
51 ***Symptoms Reported During JUUL™ Vaping***
52

53
54 Various symptoms were reported before, during, and after vaping JUUL™" Menthol"
55 pods (Figure 6A, C). While most participants generally did not report symptoms before vaping
56
57
58
59
60

1
2
3 JUUL “Menthol”, most experienced symptoms during the 20-minute vaping session. These
4 symptoms included: lightheadedness (N = 7/11), increased heart rate (N = 3/11), dry throat (N =
5
6
7 2/11), dizziness (N = 2/11), coughing (N = 2/11), nausea (N = 1/11), and shortness of breath (N
8
9 = 1/11). After the 20-minute vaping session, some symptoms (such as lightheadedness,
10
11 shortness of breath, and increased heart rate) persisted in some of the JUUL™ users. Most
12
13 symptoms were related to the neurological, respiratory, and cardiovascular systems.

14
15
16 When data were examined for individuals within the population, most did not report
17
18 symptoms before vaping; however, all except for one individual (BO) experienced symptoms
19
20 during vaping, and these persisted in all individuals except two when vaping stopped (Figure 6
21
22 B).

23
24
25 To explore a possible relationship between dose and the number of symptoms, the total
26
27 mass retained for the dominant chemicals (nicotine, menthol, and the solvents) was graphed for
28
29 each participant (Figure 6C). The mass retained for the dominant chemicals ranged from 10.8
30
31 mg to 195.4 mg based on our 21 mL/sec data during a 20-minute vaping session. The number
32
33 of symptoms was correlated to the mass retained mass retained ($R^2=0.7$) to the dose and was
34
35 significant ($p = 0.004$) (Figure 6D).

36
37
38 ***Estimated Exposure to Nicotine, Menthol, and the Solvents for a Single Puff, Session, or***
39
40 ***Whole Day Exposure to JUUL™ “Menthol” Aerosol and Cigarette Equivalency***

41
42
43 The nicotine, menthol, PG, and G mass retained (dose) were estimated for a single puff,
44
45 a single session, and a whole day for all participants based on the 21 mL/sec flow rate
46
47 (Supplementary Table 4). For all users, a single puff of JUUL™ “Menthol” delivered less than
48
49 0.5 mg of nicotine (0.002-0.33 mg) or menthol (0.002-0.05 mg). In contrast, a single puff
50
51 delivered more than 1 mg of PG (0.22 – 1.87 mg) and G (0.62-5.26 mg) (total PG + G = 0.85-
52
53 7.1mg) for eight of eleven users. The mass retained and percent delivered in a single session
54
55 for each chemical is shown in Supplementary Table 3. For the whole day estimates, nicotine
56
57
58
59
60

1
2
3 and menthol ranged from 0.3 - 46.2 mg and 0.02 – 7 mg, respectively. For the whole day
4 estimates, PG (30.8 - 261.8 mg) and G (86.8 - 736.4 mg) were delivered at much higher
5 masses than the other chemicals, and the combined solvent (119 - 998.2 mg) estimates
6 exceeded 100 mg for all users.
7
8
9
10

11 To compare the extrapolated nicotine exposure during JUUL™ vaping to cigarette
12 smoking (FTC standard protocol for Marlboro Red filtered hard pack), 1.1 mg was selected to as
13 equivalent to 1 cigarette/day and 22 mg was equivalent to 1 pack/day⁴⁶ (Supplementary Table
14 4). For the session data, the nicotine dose for JUUL™ users was equivalent to < 1 to ~8
15 cigarettes. For whole day estimates, five users were exposed to the nicotine equivalent to ~1 to
16 ~2 packs/day.
17
18
19
20
21
22
23
24
25

26 ***Nicotine, Menthol, and Solvents Deposited as ECEAR After JUUL™ Vaping***

27
28 Nicotine and menthol were detected in ECEAR extracts of paper towels that had been
29 exposed to exhale in an acrylic box (Figure 7 A,B). The total mass of nicotine and menthol in the
30 ECEAR extracts was between < 0 to 0.2 mg and < 0 to 0.9 mg, respectively (Figure 7A). Nine of
31 11 participants had more menthol than nicotine in their ECEAR. For the solvents, 0 – 3.8 mg of
32 PG and 0 – 67.4 mg of G were detected in ECEAR (Figure 7B), and the relative amounts of
33 each solvent varied with the participants. Three participants deposited both PG and G, three
34 deposited G only, and six deposited neither solvent in ECEAR.
35
36
37
38
39
40
41
42

43 Other flavor chemicals that were detected in the ECEAR included: hexanol, benzyl
44 alcohol, isoamyl isovalerate, p-tolualdehyde, acetophenone and triacetin (Supplementary Figure
45 6). In some participants, chemicals, such as hexanol, p-tolualdehyde, and triacetin, were
46 elevated in the ECEAR after vaping.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

DISCUSSION

The puffing topography, transfer efficiency of dominant chemicals, exposure, retention, and ECEAR deposition were examined during 20-minute vaping sessions, providing comprehensive data on JUUL™ “Menthol” use. Acute symptoms were also evaluated relative to the mass retained of the dominant JUUL™ chemicals, and the nicotine equivalency per single puff and day was estimated (Figure 8). Topographies varied among users but were similar for a given individual on different days. Transfer efficiencies for nicotine, menthol, WS-23, and the solvents were generally 49 - 115% at 21 mL/sec. At six flow rates, high levels of PG and G and moderate levels of nicotine and menthol were delivered to and retained by the participants. When the data were extrapolated to whole day exposures, half of the JUUL™ users received nicotine doses > 1 pack of Marlboro Red cigarettes, with one individual receiving the equivalent of 2 packs. Symptoms reported by participants during vaping had a significant correlation to the total mass of the dominant chemicals that were retained. Overall, JUUL™ “Menthol” ECs delivered high levels of chemicals and produced symptoms during vaping that sometimes persisted after the session ended.

Our concentrations of nicotine, menthol, and PG/G agree with previous studies on JUUL™ ECs⁹⁻¹¹, indicating that the chemical formulation for JUUL™ “Menthol” e-liquid has not changed in the past 3 years. Menthol concentration in JUUL™ “Menthol” pods was ~13 mg/mL, which is higher than the concentration in mentholated tobacco products (< 0.002 - 7 mg/cigarette)⁵¹, but low compared to the concentrations of nicotine and the solvents (PG and G) in JUUL™ e-liquids. Prior studies emphasized the importance of the “high” concentrations of nicotine and flavor chemicals in e-liquids^{9,41,50}; however, the solvents comprise over 90% of the chemical mixture in JUUL™ “Menthol” pods and are the major chemical that vapers receive. Although benzoic acid was not examined in the present study, it is found at 44.8 ± 0.6 mg/mL in JUUL™ pods¹².

1
2
3 Puff duration can be affected by the EC model, efficiency of nicotine delivery¹, and the
4
5 desire to create large clouds. In contrast to conventional cigarette smokers ($\sim 2.4 \pm 0.8$)^{40,52}, the
6
7 mean puff duration across all generations of EC models is 3.2 seconds^{38,40,48-49,53-55}. In a
8
9 JUUL™ study, puff duration was 3.0 ± 1.4 seconds⁴⁹, which is in reasonably good agreement
10
11 with our average puff of 4.4 ± 2.0 seconds. Longer puff duration can increase the transfer
12
13 efficiency of chemicals to aerosols³⁸, and in EC tank models, the level of toxicants, such as
14
15 acetaldehyde, acrolein, and formaldehyde, that are inhaled⁵⁶. Some reaction products, such as
16
17 hydroxyacetone, were not detected in our study, and formaldehyde and acrolein were at or
18
19 below the LOQ in another JUUL™ study¹³ and may be less of a concern than the dominant
20
21 chemicals.
22


23
24
25 TPS, which considers puff duration and puff count, is a simple rapid method for
26
27 estimating total exposure during a session. Two users (VN and BL) had TPS values < 80 on
28
29 both days and were subsequently found to have lower mass retained (exposure) than other
30
31 participants in our vaping data. In contrast, participants with high TPS received higher total
32
33 chemical exposure during vaping.
34

35
36 The chemical transfer efficiency from an e-liquid to an aerosol can be influenced by
37
38 various factors and affects the actual exposure (dose) that a vaper receives. The transfer
39
40 efficiency of nicotine, menthol, other flavor chemicals, PG, G, and benzoic acid have been
41
42 reported using various EC models and operating conditions. In older models, including
43
44 disposables, the transfer efficiency of nicotine was $< 50 - 60\%$ ^{17,57-58}. In newer models,
45
46 efficiency increased with ranges between 63 - 82% for tanks³⁸ and $\sim 50 - 80\%$ for JUUL™
47
48 products⁹⁻¹⁰. Omaiye et al (2019) reported the transfer efficiency of menthol in JUUL™
49
50 “Menthol” pods was $\sim 69\%$ at flow rates between 10 – 13 mL/s⁹, which is slightly higher than our
51
52 range (40-60%) for flow rates of 9-47 mL/sec. At either 3V or 5V, SMOK ECs transferred
53
54
55
56
57
58
59
60

1
2
3 menthol with an efficiency close to 100%⁴¹, perhaps because the pure menthol/PG mixture had
4
5 a lower boiling point than e-liquid mixtures that usually contain PG and G.

6
7
8 Since transfer efficiencies for menthol and nicotine were < 100% in our study, actual
9
10 exposures (dose) received by EC participants were lower than for the solvents (~100%
11
12 efficiency at flow rates ≥ 21 mL/sec) and lower than the concentration of the chemical in the e-
13
14 liquid. Therefore, when computing actual exposures and retention, it is necessary to consider
15
16 transfer efficiency for each chemical and the conditions used to generate aerosols. Transfer
17
18 efficiency for nicotine, menthol, and WS-23 did not increase at flow rates greater than 21
19
20 mL/sec, perhaps because their maximum efficiency is affected by the mixture of chemicals in
21
22 the JUUL™ e-liquid or the high-performance pump head. To fully understand the effect of vapor
23
24 pressure on transfer efficiency, it would be necessary to know the vapor pressure of each
25
26 chemical during heating in a mixture of chemicals in an atomizer.

27
28
29 Puff duration, EC wattage/power level, flow rate (13 and 41 mL/sec), individual
30
31 chemicals, chemical vapor pressure, vaping protocol, and the pump head affected transfer
32
33 efficiencies for laboratory generated aerosols made using a SMOK Alien EC³⁸. In general,
34
35 transfer efficiency increased with increasing puff duration, wattage, flow rate, and vapor
36
37 pressure. Our results establish transfer efficiencies for JUUL™ "Menthol" ECs and are in good
38
39 agreement with the SMOK Alien study. In our study, both PG and G transferred with very high
40
41 efficiency (~100%) at flow rates between 21 - 47 mL/sec. Poorer transfer at lower flow rates
42
43 may be due to incomplete heating of the filament, poorer efficiency of the low-performance
44
45 pump head³⁸, trapping of chemicals in the EC atomizer or pods, and greater loss of chemicals in
46
47 tubing and other parts of the aerosol collection system at the lower flow rates. The high transfer
48
49 efficiency of G is unexpected based on its low vapor pressure (0.0002 mm HG at 25°C).
50
51
52 However, inclusion of water and nicotine in G solutions lowers its boiling point⁵⁹, which would
53
54 improve its transfer into an aerosol.
55
56
57
58
59
60



1
2
3 Regardless of the model, human EC users exhale low concentrations of chemicals^{38,60-63},
4
5 which are lower than concentrations exhaled from combustible cigarettes⁶⁰⁻⁶¹. The exhale of
6
7 JUUL™ users had 99% less formaldehyde and carbon monoxide than that of traditional
8
9 smokers⁶³. Participants using blu™ disposable “Classic Tobacco” and “Menthol” ECs and other
10
11 cig-a-like and sub-ohm models had little solvent and nicotine in their exhale^{60,62}. Phenolics and
12
13 carbonyls were not detectable⁶⁰, but some TSNA and copper (< LOQ-2.92 ng) were present⁶².
14
15 We found that the exhale from JUUL™ “Menthol” users had very low concentrations of solvents
16
17 (PG and G), nicotine, and menthol.
18
19

20 Exhale content is influenced by whether a user inhales into their lungs (lung inhaler) or
21
22 their mouth (mouth inhaler)³⁸. For mouth inhalers, but not lung inhalers, chemical concentration
23
24 in the exhale was significantly correlated with longer puff durations³⁸. The 10 lung inhalers in our
25
26 study had a low total mass of chemicals (< 1 mg) in their exhale, except for one participant (BL),
27
28 whose total exhaled mass (~1 mg) was in the range of mouth inhalers using tank models³⁸.
29
30


31 Minor chemicals, such as benzaldehyde, triacetin, and acetophenone, were detected in
32
33 participants' exhale. Triacetin, a PG and G related chemical, was found only in EC users'
34
35 exhaled aerosol and was elevated shortly after vaping, suggesting rapid formation in the oral
36
37 cavity. Acetophenone and benzaldehyde were identified in both EC user and control breath, and
38
39 they are common chemicals found in human breath^{64,65}. The presence of triacetin in the exhaled
40
41 aerosol of vapers suggests it may be an exposure biomarker related to JUUL™ use.
42
43
44

45 Nicotine rapidly enters the plasma of EC users, but little is known about its actual
46
47 retention (dose). Chemical retention can be estimated using the transfer efficiency of a
48
49 chemical, the exposure a user receives, and the concentration of the chemical in the exhale.
50
51 Retention data characterize the chemical dose the oral cavity and lungs receive. Lung inhalers
52
53 retained 80 - 100% of the nicotine and flavor chemicals that they took in when using a tank style
54
55 EC³⁸. For 10 of 11 participants in our study, 86 -100% of the inhaled nicotine and menthol were
56
57
58
59
60

1
2
3 retained, and 99 - 100% of the solvents were retained at 21 mL/sec. Although we did not report
4
5 on benzoic acid, JUUL™ Crème Brûlée aerosols contained 86.9 µg/puff of benzoic acid¹⁷. Based
6
7 on our average of ~20 puffs/session, a user in our study would have been exposed to ~1.7 mg
8
9 of benzoic acid in a session. Due to its low volatility, it is likely benzoic acid was retained by the
10
11 participants.
12

13
14 Our study is the first to demonstrate that symptoms increase in JUUL™ users with
15
16 increasing chemical dose. The main ingredients in JUUL™ “Menthol” (nicotine, benzoic acid,
17
18 and solvents) can produce the reported symptoms. Nicotine can cause nausea, dizziness,
19
20 headache, and increased heart rate⁶⁶. PG and G are associated with nausea, vomiting,
21
22 headache, dizziness, lightheadedness, and skin/eye/lung irritation^{67,68}. Benzoic acid is a
23
24 respiratory irritant that can cause coughing and sore throat⁶⁹. The overlap between the
25
26 symptoms associated with nicotine, PG, G, and benzoic acid exposure suggest that the adverse
27
28 effects reported by users were caused by a combination of chemicals rather than an individual
29
30 chemical. In addition, there was a direct correlation between the dose a participant received,
31
32 and the number of symptoms reported. This is the first-time exposures were correlated to
33
34 symptoms during JUUL™ vaping. The long-term effects of persistent direct inhalation of EC
35
36 aerosols are unknown but studies suggest that exposure to the solvents cause inflammatory
37
38 effects³⁴.
39
40

41
42 Thirdhand smoke (THS), the chemical residue deposited on indoor surfaces after
43
44 cigarette smoking has stopped, has been studied extensively⁷⁰⁻⁷². THS contains high
45
46 concentrations of nicotine and related alkaloids, including carcinogens^{73,74} and accumulates with
47
48 increased cigarette use⁷⁵. A similar relationship has been reported in a vape shop in southern
49
50 California, where ECEAR (the EC counterpart of THS) accumulated over time reaching 3.6 mg
51
52 of nicotine per gram of fabric by 1 month of sampling³⁶. THS has caused adverse health effects
53
54
55
56
57
58
59
60



1
2
3 in humans following dermal and inhalation exposure^{76,77}; however, little is known about the
4
5 effects of ECEAR on human health.

6
7
8 Because retention of inhaled EC chemicals was high in most JUUL™ users, the
9
10 concentrations of exhaled nicotine, menthol, PG, and G were low and accordingly their
11
12 contributions to ECEAR were a small percent of the total chemicals in an EC puff. The ratio of
13
14 exhaled nicotine/menthol varied among participants, indicating individual variation in the relative
15
16 amounts of these chemicals retained. JUUL™ ECs produce a thin wispy aerosol, often
17
18 facilitating their stealth use. In contrast, many ECs produce larger clouds than JUUL™, and
19
20 these likely contain higher concentrations of chemicals than we observed with JUUL™ users.

21
22
23 The JUUL™ ECEAR in our study after aging for 30 minutes produced additional
24
25 chemicals that were not in the exhaled aerosol, such as p-tolualdehyde (a skin irritant) and
26
27 hexanol (central nervous system toxicant)^{78,79}. Vapers and non-vapers occupying Indoor
28
29 environments containing ECEAR would be passively exposed, mainly dermally and via
30
31 inhalation, to the chemicals in ECEAR. While adverse health effects have not yet been linked
32
33 directly to ECEAR, a better understanding of ECEAR exposures is an important knowledge gap
34
35 to be filled.
36

37 38 **Study Limitations** 39

40
41 Our data were derived from a cohort of male JUUL™ users from various ethnicities.
42
43 JUUL™ users were chosen because this was the most popular EC brand at the time the study
44
45 was started. Future studies could be extended to third generation and other fourth generation
46
47 EC brands, which are currently popular. Our data are based on JUUL™ ECs, which deliver
48
49 relatively small clouds of aerosol. Third generation products, which deliver large aerosol
50
51 volumes, may result in larger quantities of chemicals being retained and exhaled. We limited our
52
53 study to male participants, since EC use is more prevalent among males than females⁸⁰. The
54
55 retention and exhale data were similar across the 11 participants in our study, suggesting these
56
57
58
59
60


1
2
3 data are representative of JUUL™ users in general. Future studies could be extended to a
4
5 larger population that includes representatives from more ethnicities and females.
6

7 8 **Conclusion Paragraph** 9

10 We provide a comprehensive overview of exposure, retention, and ECEAR deposition
11 for JUUL™ “Menthol” users. Nicotine, menthol, PG, and G were transferred with variable
12 efficiency to EC aerosols and well retained by participants. The total mass retained (dose) in a
13 20-minute vaping session (calculated at 21 mL/sec) ranged from 10.8 to 195 mg for the
14 dominant chemicals. Retention of PG and G was close to 100% in most participants, and as a
15 consequence relatively low levels of chemicals appeared in ECEAR. Most users reported
16 adverse symptoms, such as -nausea, dizziness and lightheadedness, during the 20-minute
17 vaping session, and there was a significant correlation between the dose and symptom count.
18
19 The potential doses JUUL™ users receive of nicotine, PG, and G are concerning, especially the
20 solvents which are understudied. Additionally, the potential for higher delivery and higher
21 deposition of ECEAR may exist in other products, such as EC tanks/mods. Although there are
22 few chemicals in JUUL™ pods, the potential for chemical transfer is high and there is the
23 possibility for the formation of toxic byproducts in ECEAR that can contribute to passive
24 exposure over time. Going forward, it will be important to conduct similar studies using other EC
25 products and to follow the long-term health effects of both JUUL™ use and passive exposure of
26 non-users to ECEAR.
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42

43
44
45 **Supporting Information:** Additional experimental details, data, and terms/abbreviations are
46 included (PDF).
47

48
49 **Acknowledgments:** We would like to thank Girija Vasdevan for her assistance with collecting
50 some of the aerosol samples.
51
52
53
54
55
56
57
58
59
60



1
2
3 **Contributors:** Conception and design: MH, PT, and CK. Sample preparation and data
4 collection: MH, SL, TM and CK. Chemical analysis: WL and KM. Data interpretation: MH and
5
6 PT. Data analysis and writing of the manuscript: MH and PT. Editing the manuscript: MH, PT,
7
8 WL, and CK.
9

10
11
12 **Funding:** This research was supported by Grant #26IR-0018 from the Tobacco-Related
13 Disease Research Program of California (TRDRP) to PT. MH was supported by a TRDRP
14 Predoctoral Fellowship (#28DT-0009), a Graduate Fund provided by the Leonard Family
15 Foundation, and Dissertation Year Program Award from the Environmental Toxicology Program
16
17 and UCR Graduate Division. GraphPad Prism software was purchased by the California
18
19 Department of Rehabilitation for MH. The content is solely the responsibility of the authors and
20 does not necessarily represent the official views of TRDRP or other granting agencies.
21
22
23
24
25
26
27
28
29

30 **Competing financial interests:** All authors declare that they have no actual or potential
31 competing financial interest.
32
33
34
35

36 **Patient consent:** Yes
37

38
39 **Provenance and peer review:** Not commissioned; externally peer reviewed.
40
41

42 **Data sharing statement:** All relevant data are included in the manuscript.
43
44

45 **FIGURE LEGENDS**

46
47 **Figure 1: Mass Transfer and Percent Efficiency of Nicotine, Menthol, and the Solvents in**
48 **JUUL™ “Menthol” Pods at Various Flow Rates. (A-F)** The transfer efficiencies of nicotine,
49 menthol, propylene glycol, and glycerol were estimated at six flow rates 9, 11, 13, 21, 41, and
50 47 mL/sec. The mass (mg) of the chemical transferred from liquid to aerosol during
51 aerosolization is shown in their respective flow rate bars. The averaged transfer efficiency and
52 mass (mg) transferred are shown for nicotine, menthol, WS-23, propylene glycol, and glycerol at
53 the six flow rates. * = $p < 0.05$; ** = $p < 0.01$; *** = $p < 0.001$; **** = $p < 0.0001$.
54
55
56
57
58
59
60

1
2
3 **Figure 2: Mass Transfer and Percent Efficiency of Nicotine, Menthol, WS-23 and the**
4 **Solvents in JUUL™ “Menthol” Pods Plotted at Various Flow Rates. (A-E)** The transfer
5 efficiency of nicotine, menthol, WS-23, propylene glycol, and glycerol were plotted separately at
6 various flow rates 9, 11, 13, 21, 41, and 47 mL/sec. The mass (mg) of the chemical transferred
7 from liquid to aerosol during aerosolization is shown in their respective flow rate bars. * = $p <$
8 0.05; ** = $p <$ 0.01; *** = $p <$ 0.001.
9

10
11 **Figure 3: Maximal and Actual Exposure for Each Dominant Chemical.** The estimated
12 maximal and actual exposures (A-D) and their averages \pm SD were calculated for nicotine,
13 menthol, PG, and G as described in the Materials & Methods. Light Red = maximal exposure;
14 Red = actual exposure.
15

16 **Figure 4: Total Exhale Quantified for Each Participant During Day 2 Session.** (A) The total
17 exhale (mg) for nicotine, menthol, and WS-23 quantified for each user. (B) The total exhale (mg)
18 for propylene glycol and glycerol quantified for each user.
19

20 **Figure 5: Mass and Percent Retained Calculated for Nicotine, Menthol, PG, and G at 21**
21 **mL/sec for Each User.** The estimated mass delivered (A, C, E, G) and percent retention (B, D,
22 F, H) was computed by calculating the amount of nicotine, menthol, PG, and G consumed and
23 subtracting from this from the amount of nicotine, menthol, PG, and G exhaled.
24

25 **Figure 6: Acute Symptoms Observed for Users During Exhale Session.** (A-B) The most
26 reported symptoms before, during, and after vaping are shown along with the average number
27 of symptoms reported during Day 1 and 2 sessions. (C) Total exposure calculated for vapers
28 from all four chemicals. (D) The correlation between the number of symptoms (Y-axis) and the
29 total chemical mass retained (X-axis).
30

31 **Figure 7: Total ECEAR Concentrations for Each Participant During Day 1 Session.** (A) The
32 total ECEAR mass (mg) in the acrylic box for nicotine and menthol for each user. (B) The total
33 ECEAR mass (mg) in the acrylic box for PG and G for each user.
34
35

36 **Figure 8: Summary of Major Results.**
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. National Academies of Sciences, Engineering, and Medicine. Public health consequences of e-cigarettes.
2. Williams M, Talbot P. Design features in multiple generations of electronic cigarette atomizers. *International journal of environmental research and public health*. 2019 Aug;16(16):2904.
3. Huang J, Duan Z, Kwok J, Binns S, Vera LE, Kim Y, Szczypka G, Emery SL. Vaping versus JUUL™ing: how the extraordinary growth and marketing of JUUL™ transformed the US retail e-cigarette market. *Tob Control*. 2019 Mar;28(2):146-151. doi: 10.1136/tobaccocontrol-2018-054382. Epub 2018 May 31. PMID: 29853561; PMCID: PMC6274629.
4. Wang TW, Neff LJ, Park-Lee E, et al. E-cigarette Use Among Middle and High School Students - United States, 2020. *MMWR Morb Mortal Wkly Rep* 2020;69:1310–2. 26
5. Wang TW, Gentzke AS, Neff LJ, et al. Disposable E-Cigarette Use among U.S. Youth - An Emerging Public Health Challenge. *N Engl J Med* 2021;384:1573–6.
6. Lee YO, Nonnemaker JM, Bradfield B, Hensel EC, Robinson RJ. Examining daily electronic cigarette puff topography among established and nonestablished cigarette smokers in their natural environment. *Nicotine and Tobacco Research*. 2018 Sep 4;20(10):1283-8.
7. United States Food and Drug Administration. Premarket tobacco product marketing granted orders, 2022. Available: <https://www.fda.gov/tobacco-products/premarket-tobacco-product-applications/premarket-tobacco-product-marketing-granted-orders> [Accessed 27 June 2022].

- 1
2
3 8. Jewett, Christina. F.D.A. Lets Juul Appeal Ban and Stay on the Market During a Review.
4
5 July 6, 2022. Available: [https://www.nytimes.com/2022/07/06/health/juul-fda-](https://www.nytimes.com/2022/07/06/health/juul-fda-ecigarettes.html)
6
7 [ecigarettes.html](https://www.nytimes.com/2022/07/06/health/juul-fda-ecigarettes.html) [Accessed 10 October 2022].
8
- 9
10 9. Omaiye EE, McWhirter KJ, Luo W, Pankow JF, Talbot P. High-Nicotine Electronic
11
12 Cigarette Products: Toxicity of JUUL™ Fluids and Aerosols Correlates Strongly with
13
14 Nicotine and Some Flavor Chemical Concentrations. *Chem Res Toxicol*. 2019 Jun
15
16 17;32(6):1058-1069. doi: 10.1021/acs.chemrestox.8b00381. Epub 2019 Apr 17. PMID:
17
18 30896936; PMCID: PMC6579667.
- 19
20 10. Erythropel HC, Davis LM, de Winter TM, Jordt SE, Anastas PT, O'Malley SS, Krishnan-
21
22 Sarin S, Zimmerman JB. Flavorant–solvent reaction products and menthol in JUUL e-
23
24 cigarettes and aerosol. *American journal of preventive medicine*. 2019 Sep 1;57(3):425-
25
- 26
27 11. Talih S, Salman R, El-Hage R, Karam E, Karaoghlanian N, El-Hellani A, Saliba N,
28
29 Shihadeh A. Characteristics and toxicant emissions of JUUL™ electronic cigarettes. *Tob*
30
31 *Control*. 2019 Nov;28(6):678-680. doi: 10.1136/tobaccocontrol-2018-054616. Epub 2019
32
33 Feb 11. PMID: 30745326; PMCID: PMC7341718.
- 34
35 12. Pankow JF, Kim K, McWhirter KJ, Luo W, Escobedo JO, Strongin RM, Duell AK, Peyton
36
37 DH. Benzene formation in electronic cigarettes. *PloS one*. 2017 Mar 8;12(3):e0173055.
38
- 39
40 13. Pinkston R, Zaman H, Hossain E, Penn AL, Noël A. Cell-specific toxicity of short-term
41
42 JUUL aerosol exposure to human bronchial epithelial cells and murine macrophages
43
44 exposed at the air–liquid interface. *Respiratory research*. 2020 Dec;21(1):1-5.
- 45
46 14. Ghosh A, Beyazcicek O, Davis ES, Onyenwoke RU, Tarran R. Cellular effects of
47
48 nicotine salt-containing e-liquids. *Journal of Applied Toxicology*. 2021 Mar;41(3):493-
49
50 505.
- 51
52 15. Nair V, Tran M, Behar RZ, Zhai S, Cui X, Phandthong R, Wang Y, Pan S, Luo W,
53
54 Pankow JF, Volz DC. Menthol in electronic cigarettes: A contributor to respiratory
55
56 disease?. *Toxicology and applied pharmacology*. 2020 Nov 15;407:115238.
57
58
59
60

- 1
2
3 16. Zhang R, Jones MM, Dornsife RE, Wu T, Sivaraman V, Tarran R, Onyenwoke RU.
4
5 JUUL e-liquid exposure elicits cytoplasmic Ca²⁺ responses and leads to cytotoxicity in
6
7 cultured airway epithelial cells. *Toxicology letters*. 2021 Feb 1;337:46-56.
8
9
10 17. Lamb T, Muthumalage T, Rahman I. Pod-based menthol and tobacco flavored e-
11
12 cigarettes cause mitochondrial dysfunction in lung epithelial cells. *Toxicology letters*.
13
14 2020 Oct 15;333:303-11.
15
16 18. Wick KD, Fang X, Maishan M, Matsumoto S, Spottiswoode N, Sarma A, Simoneau C,
17
18 Khakoo M, Langelier C, Calfee CS, Gotts JE. Impact of e-cigarette aerosol on primary
19
20 human alveolar epithelial type 2 cells. *American Journal of Physiology-Lung Cellular and*
21
22 *Molecular Physiology*. 2022 Aug 1;323(2):L152-64.
23
24 19. Ramenzoni LL, Schneider A, Fox SC, Meyer M, Meboldt M, Attin T, Schmidlin PR.
25
26 Cytotoxic and Inflammatory Effects of Electronic and Traditional Cigarettes on Oral
27
28 Gingival Cells Using a Novel Automated Smoking Instrument: An In Vitro Study. *Toxics*.
29
30 2022 Apr 6;10(4):179.
31
32 20. Rao P, Liu J, Springer ML. JUUL and combusted cigarettes comparably impair
33
34 endothelial function. *Tobacco regulatory science*. 2020 Jan 1;6(1):30-7.
35
36 21. Rao P, Han DD, Tan K, Mohammadi L, Derakhshandeh R, Navabzadeh M, Goyal N,
37
38 Springer ML. Comparable impairment of vascular endothelial function by a wide range of
39
40 electronic nicotine delivery devices. *Nicotine and Tobacco Research*. 2022
41
42 Jul;24(7):1055-62.
43
44 22. Ramirez JE, Karim ZA, Alarabi AB, Hernandez KR, Taleb ZB, Rivera JO, Khasawneh
45
46 FT, Alshbool FZ. The JUUL e-cigarette elevates the risk of thrombosis and potentiates
47
48 platelet activation. *Journal of Cardiovascular Pharmacology and Therapeutics*. 2020
49
50 Nov;25(6):578-86.
51
52
53
54
55
56
57
58
59
60

- 1
2
3 23. Sifat AE, Archie SR, Nozohouri S, Villalba H, Ghanwatkar Y, Sharma S, Zhang Y,
4
5 Vaidya B, Cucullo L, Abbruscato TJ. Short-term Exposure to JUUL Electronic Cigarettes
6
7 Can Worsen Ischemic Stroke Outcome by Disrupting the Blood-Brain Barrier.
8
9
10 24. Moshensky A, Brand CS, Alhaddad H, Shin J, Masso-Silva JA, Advani I, Gunge D,
11
12 Sharma A, Mehta S, Jahan A, Nilaad S. Effects of mango and mint pod-based e-
13
14 cigarette aerosol inhalation on inflammatory states of the brain, lung, heart, and colon in
15
16 mice. *Elife*. 2022 Apr 12;11:e67621.
17
18 25. Lorkiewicz P, Keith R, Lynch J, Jin L, Theis W, Krivokhizhina T, Riggs D, Bhatnagar A,
19
20 Srivastava S, Conklin DJ. Electronic Cigarette Solvents, JUUL E-Liquids, and
21
22 Biomarkers of Exposure: In Vivo Evidence for Acrolein and Glycidol in E-Cig-Derived
23
24 Aerosols. . 2022 Jan 19;35(2):283-92.
25
26 26. Been T, Traboulsi H, Paoli S, Alakhtar B, Mann KK, Eidelman DH, Baglolle CJ.
27
28 Differential impact of JUUL flavors on pulmonary immune modulation and oxidative
29
30 stress responses in male and female mice. *Archives of Toxicology*. 2022
31
32 Jun;96(6):1783-98.
33
34 27. Cahill KM, Johnson TK, Perveen Z, Schexnayder M, Xiao R, Heffernan LM, Langohr IM,
35
36 Paulsen DB, Penn AL, Noël A. In utero exposures to mint-flavored JUUL aerosol impair
37
38 lung development and aggravate house dust mite-induced asthma in adult offspring
39
40 mice. *Toxicology*. 2022 Jul 1;477:153272.
41
42
43 28. Luo J, Chen L, Lu X, Yuan J, Xie Z, Li D. Analysis of potential associations of JUUL
44
45 flavours with health symptoms based on user-generated data from Reddit. *Tobacco*
46
47 *control*. 2021 Sep 1;30(5):534-41.
48
49
50 29. Hong T, Wu J, Wijaya D, Xuan Z, Fetterman JL. JUUL the heartbreaker: Twitter analysis
51
52 of cardiovascular health perceptions of vaping. *Tobacco induced diseases*. 2021;19.
53
54 30. Wagoner KG, King JL, Alexander A, Tripp HL, Sutfin EL. Adolescent Use and
55
56 Perceptions of JUUL and Other Pod-Style e-Cigarettes: A Qualitative Study to Inform
57
58
59
60

1
2
3 Prevention. International Journal of Environmental Research and Public Health. 2021
4
5 May 1;18(9):4843.

- 6
7
8 31. Li W, Vargas-Rivera M, Eissenberg TE, Shihadeh A, Talih S, Maziak W. Effect of
9
10 menthol/mint-flavored pods on young JUUL E-cigarette users' subjective experience,
11
12 puffing behavior, and nicotine exposure: A pilot study. Drug and Alcohol Dependence.
13
14 2022 May 31:109516.
- 15
16 32. Mantey DS, Case KR, Omega-Njemnobi O, Springer AE, Kelder SH. Use frequency and
17
18 symptoms of nicotine dependence among adolescent E-cigarette users: Comparison of
19
20 JUUL and Non-JUUL users. Drug and Alcohol Dependence. 2021 Nov 1;228:109078.
- 21
22 33. Gonzalez JE, Cooke WH. Acute effects of electronic cigarettes on arterial pressure and
23
24 peripheral sympathetic activity in young nonsmokers. American Journal of Physiology -
25
26 Heart and Circulatory Physiology. 2021 Jan 1;320(1):H248-55.
- 27
28 34. Song M, Reisinger SA, Freudenheim JL, Brasky TM, Mathé EA, McElroy JP, Nickerson
29
30 QA, Weng DY, Wewers MD, Shields PG. Effects of Electronic Cigarette Constituents on
31
32 the Human Lung: A Pilot Clinical TrialEffects of Electronic Cigarette on the Human Lung.
33
34 Cancer Prevention Research. 2020 Feb 1;13(2):145-52.
- 35
36 35. Khachatoorian C, Jacob III P, Sen A, Zhu Y, Benowitz NL, Talbot P. Identification and
37
38 quantification of electronic cigarette exhaled aerosol residue chemicals in field sites.
39
40 Environmental research. 2019 Mar 1;170:351-8.
- 41
42 36. Khachatoorian C, Jacob lii P, Benowitz NL, Talbot P. Electronic cigarette chemicals
43
44 transfer from a vape shop to a nearby business in a multiple-tenant retail building. Tob
45
46 Control. 2019 Sep;28(5):519-525. doi: 10.1136/tobaccocontrol-2018-054316. Epub 2018
47
48 Aug 29. PMID: 30158206; PMCID: PMC6458093.
- 49
50 37. Khachatoorian C, Luo W, McWhirter KJ, Pankow JF, Talbot P. E-cigarette fluids and
51
52 aerosol residues cause oxidative stress and an inflammatory response in human
53
54 keratinocytes and 3D skin models. Toxicology in Vitro. 2021 Dec 1;77:105234.
- 55
56
57
58
59
60

- 1
2
3 38. Khachatoorian C, McWhirter KJ, Luo W, Pankow JF, Talbot P. Tracing the movement of
4
5 electronic cigarette flavor chemicals and nicotine from refill fluids to aerosol, lungs,
6
7 exhale, and the environment. *Chemosphere*. 2022 Jan 1;286:131494.
8
9
10 39. Omaiye EE, Cordova I, Davis B, Talbot P. Counterfeit electronic cigarette products with
11
12 mislabeled nicotine concentrations. *Tobacco regulatory science*. 2017 Jul 1;3(3):347-57.
13
14 40. Hua M, Yip H, Talbot P. Mining data on usage of electronic nicotine delivery systems
15
16 (ENDS) from YouTube videos. *Tobacco control*. 2013 Mar 1;22(2):103-6.
17
18 41. Behar RZ, Luo W, McWhirter KJ, Pankow JF, Talbot P. Analytical and toxicological
19
20 evaluation of flavor chemicals in electronic cigarette refill fluids. *Sci Rep*. 2018 May
21
22 29;8(1):8288. doi: 10.1038/s41598-018-25575-6. PMID: 29844439; PMCID:
23
24 PMC5974410.
25
26 42. Knoll M., Talbot P. (1998). Cigarette smoke inhibits oocyte cumulus complex pick-up by
27
28 the oviduct in vitro independent of ciliary beat frequency. *Reproductive Toxicology*, 12,
29
30 57–68. 10.1016/S0890-6238(97)00100-7
31
32
33 43. Hensel EC, Eddingsaas NC, Saleh QM, Jayasekera S, Sarles SE, Thomas M, Myers
34
35 BT, DiFrancesco G, Robinson RJ. Nominal Operating Envelope of Pod and Pen Style
36
37 Electronic Cigarettes. *Frontiers in Public Health*. 2021:1201.
38
39 44. Tierney PA, Karpinski CD, Brown JE, Luo W, Pankow JF. Flavour chemicals in
40
41 electronic cigarette fluids. *Tobacco control*. 2016 Apr 1;25(e1):e10-5.
42
43 45. Dautzenberg B, Bricard D. Real-time characterization of e-cigarettes use: the 1 million
44
45 puffs study. *J. Addict. Res. Ther.* 2015;6(229.10):4172.
46
47 46. Federal Trade Commission. "Tar," nicotine, and carbon monoxide of the smoke of
48
49 1294 varieties of domestic cigarettes for the year 1998, 2000.
50
51
52 47. Foulds J, Veldheer S, Yingst J, Hrabovsky S, Wilson SJ, et al. Development of a
53
54 questionnaire for assessing dependence on electronic cigarettes among a large sample
55
56
57
58
59
60

1
2
3 of ex-smoking E-cigarette users. *Nicotine Tob Res.* 2015 Feb;17(2):186-92.

4
5 <https://doi.org/10.1093/ntr/ntu204>

- 6
7
8 48. Helen GS, Ross KC, Dempsey DA, Havel CM, Jacob P, Benowitz NL. Nicotine delivery
9 and vaping behavior during ad libitum e-cigarette access. *Tobacco Regulatory Science.*
10 2016 Oct 1;2(4):363-76.
11
12
13 49. Vargas-Rivera M, Kalan ME, Ward-Peterson M, Osibogun O, Li W, Brown D, Eissenberg
14 T, Maziak W. Effect of flavour manipulation on ENDS (JUUL) users' experiences, puffing
15 behaviour and nicotine exposure among US college students. *Tobacco control.* 2021 Jul
16 1;30(4):399-404.
17
18
19 50. Hua M, Omaiye EE, Luo W, McWhirter KJ, Pankow JF, Talbot P. Identification of
20 cytotoxic flavor chemicals in top-selling electronic cigarette refill fluids. *Scientific reports.*
21 2019 Feb 26;9(1):1-5.
22
23
24 51. Ai J, Taylor KM, Lisko JG, Tran H, Watson CH, Holman MR. Menthol content in US
25 marketed cigarettes. *Nicotine & Tobacco Research.* 2015 Aug 9;18(7):1575-80.
26
27
28 52. Dickens C, McGrath C, Warren N, Biggs P, McAughey J. Puffing and inhalation
29 behaviour in cigarette smoking: Implications for particle diameter and dose. In *Journal of*
30 *Physics: Conference Series* 2009 Feb 1 (Vol. 151, No. 1, p. 012019). IOP Publishing.
31
32
33 53. Behar RZ, Hua M, Talbot P. Puffing topography and nicotine intake of electronic
34 cigarette users. *PLoS One.* 2015 Feb 9;10(2):e0117222. doi:
35 10.1371/journal.pone.0117222. PMID: 25664463; PMCID: PMC4321841.
36
37
38 54. Robinson RJ, Hensel EC, Morabito PN, Roundtree KA. Electronic cigarette topography
39 in the natural environment. *PloS one.* 2015 Jun 8;10(6):e0129296.
40
41
42 55. Park-Lee E, Ren C, Sawdey MD, et al. Notes from the field: E-Cigarette use among
43 middle and high school students - National Youth Tobacco Survey, United States, 2021.
44 *MMWR Morb Mortal Wkly Rep* 2021;70:1387-9.
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 56. Ogunwale MA, Li M, Ramakrishnam Raju MV, Chen Y, Nantz MH, Conklin DJ, Fu XA.
4 Aldehyde detection in electronic cigarette aerosols. ACS omega. 2017 Mar
5 31;2(3):1207-14.
6
7
8
9 57. Pagano T, DiFrancesco AG, Smith SB, George J, Wink G, Rahman I, Robinson RJ.
10 Determination of nicotine content and delivery in disposable electronic cigarettes
11 available in the United States by gas chromatography-mass spectrometry. Nicotine &
12 Tobacco Research. 2016 May 1;18(5):700-7.
13
14
15
16 58. Goniewicz ML, Kuma T, Gawron M, Knysak J, Kosmider L. Nicotine levels in electronic
17 cigarettes. Nicotine & Tobacco Research. 2013 Jan 1;15(1):158-66.
18
19
20 59. Duell AK, Pankow JF, Gillette SM, Peyton DH. Boiling points of the propylene glycol+
21 glycerol system at 1 atmosphere pressure: 188.6–292 C without and with added water or
22 nicotine. Chemical engineering communications. 2018 Dec 2;205(12):1691-700.
23
24
25
26 60. Long GA. Comparison of select analytes in exhaled aerosol from e-cigarettes with
27 exhaled smoke from a conventional cigarette and exhaled breaths. International journal
28 of environmental research and public health. 2014 Nov;11(11):11177-91.
29
30
31 61. Czogala J, Goniewicz ML, Fidelus B, Zielinska-Danch W, Travers MJ, Sobczak A.
32 Secondhand exposure to vapors from electronic cigarettes. nicotine & tobacco research.
33 2014 Jun 1;16(6):655-62.
34
35
36 62. Visser WF, Klerx WN, Cremers HW, Ramlal R, Schwillens PL, Talhout R. The health
37 risks of electronic cigarette use to bystanders. International journal of environmental
38 research and public health. 2019 May;16(9):1525.
39
40
41 63. Goldenson NI, Fearon IM, Buchhalter AR, Henningfield JE. An open-label, randomized,
42 controlled, crossover study to assess nicotine pharmacokinetics and subjective effects of
43 the JUUL system with three nicotine concentrations relative to combustible cigarettes in
44 adult smokers. Nicotine and Tobacco Research. 2021 Jun;23(6):947-55.
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 64. Yamanaka HR, Cheung C, Mendoza JS, Oliva DJ, Elzey-Aberilla K, Perrault KA. Pilot
4 study on exhaled breath analysis for a healthy adult population in Hawaii. *Molecules*.
5 2021 Jun 18;26(12):3726.
6
7
8
9 65. Wang P, Huang Q, Meng S, Mu T, Liu Z, He M, Li Q, Zhao S, Wang S, Qiu M.
10 Identification of lung cancer breath biomarkers based on perioperative breathomics
11 testing: A prospective observational study. *EClinicalMedicine*. 2022 May 1;47:101384.
12
13 66. Fotedar S, Fotedar V. Green tobacco sickness: a brief review. *Indian journal of*
14 *occupational and environmental medicine*. 2017 Sep;21(3):101.
15
16 67. New Jersey Department of Health. Propylene Glycol: Hazardous Fact Sheet. Available:
17 <https://nj.gov/health/eoh/rtkweb/documents/fs/3595.pdf>. [Accessed: 10 October 2022]
18
19 68. Mayo Clinic. Glycerin (Oral Route). Available: [https://www.mayoclinic.org/drugs-](https://www.mayoclinic.org/drugs-supplements/glycerin-oral-route/side-effects/drg-20067747)
20 [supplements/glycerin-oral-route/side-effects/drg-20067747](https://www.mayoclinic.org/drugs-supplements/glycerin-oral-route/side-effects/drg-20067747). [Accessed: 10 October
21 2022]
22
23 69. New Jersey Department of Health. Benzoic Acid: Hazardous Fact Sheet. Available:
24 <https://www.nj.gov/health/eoh/rtkweb/documents/fs/0209.pdf>. [Accessed: 10 October
25 2022]
26
27 70. Matt GE, Quintana PJ, Fortmann AL, Zakarian JM, Galaviz VE, Chatfield DA, et al.
28 (2013). Thirdhand smoke and exposure in California hotels: non-smoking rooms fail to
29 protect non-smoking hotel guests from tobacco smoke exposure. *Tobacco Control*. doi:
30 10.1136/tobaccocontrol-2012-050824. PubMed PMID: 23669058.
31
32 71. Northrup, T. F., G. E. Matt, M. F. Hovell, A. M. Khan and A. L. Stotts (2015). "Thirdhand
33 Smoke in the Homes of Medically Fragile Children: Assessing the Impact of Indoor
34 Smoking Levels and Smoking Bans." *Nicotine Tob Res*. doi: 10.1093/ntr/ntv174
35
36 72. Jacob III P, Benowitz NL, Destailats H, Gundel L, Hang B, Martins-Green M, Matt GE,
37 Quintana PJ, Samet JM, Schick SF, Talbot P. Thirdhand smoke: new evidence,
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 challenges, and future directions. . 2017 Jan

4
5 17;30(1):270-94.

6
7 73. Sleiman M, Gundel LA, Pankow JF, Jacob III P, Singer BC, Destailats H. Formation of
8
9 carcinogens indoors by surface-mediated reactions of nicotine with nitrous acid, leading
10
11 to potential thirdhand smoke hazards. Proceedings of the National Academy of
12
13 Sciences. 2010 Apr 13;107(15):6576-81.

14
15 74. Bahl V., Weng N.J.-H., Schick S.F., Sleiman M., Whitehead J., Ibarra A., Talbot P.
16
17 Cytotoxicity of Thirdhand Smoke and Identification of Acrolein as a Volatile Thirdhand
18
19 Smoke Chemical That Inhibits Cell Proliferation. Toxicol. Sci. 2015;150:234–246. doi:
20
21 10.1093/toxsci/kfv327. [PubMed] [CrossRef] [Google Scholar]

22
23 75. Bahl V., Johnson K., Phandthong R., Zahedi A., Schick S.F., Talbot P. Thirdhand
24
25 cigarette smoke causes stress-induced mitochondrial hyperfusion and alters the
26
27 transcriptional profile of stem cells. Toxicol. Sci. 2016;153:55–69. doi:
28
29 10.1093/toxsci/kfw102.

30
31 76. Pozuelos GL, Jacob III P, Schick SF, Omaiye EE, Talbot P. Adhesion and Removal of
32
33 Thirdhand Smoke from Indoor Fabrics: A Method for Rapid Assessment and
34
35 Identification of Chemical Repositories. International journal of environmental research
36
37 and public health. 2021 Mar 30;18(7):3592.

38
39 77. Sakamaki-Ching S, Schick S, Grigorean G, Li J, Talbot P. Dermal thirdhand smoke
40
41 exposure induces oxidative damage, initiates skin inflammatory markers, and adversely
42
43 alters the human plasma proteome. EBioMedicine. 2022 Oct 1;84:104256.

44
45 78. Fisher Scientific. P-Tolualdehyde: Data Safety Sheet. Available:

46
47 <https://www.fishersci.com/store/msds?partNumber=AC139005000&productDescription=>

48
49 P-

50
51 TOLUALDEHYDE%2C+97%25+500GR&vendorId=VN00032119&countryCode=US&lan
52
53 guage=en. [Accessed: 10 October 2022]



1
2
3 79. Parchem. Hexanol: Safety Data Sheet. Available:

4
5 <https://www.parchem.com/siteimages/Attachment/GHS%20Hexanol%20MSDS.pdf> .

6
7 [Accessed 10 October 2022]

8
9 80. Rodríguez-Bolaños R, Arillo-Santillán E, Barrientos-Gutiérrez I, Zavala-Arciniega L,
10 Ntansah CA, Thrasher JF. Sex differences in becoming a current electronic cigarette
11 user, current smoker and current dual user of both products: a longitudinal study among
12 Mexican adolescents. *International journal of environmental research and public health*.
13 2020 Jan;17(1):196.
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60






Figure 1: Mass Transfer and Percent Efficiency of Nicotine, Menthol, and the Solvents in JUUL™ “Menthol” Pods at Various Flow Rates. (A-F) The transfer efficiencies of nicotine, menthol, propylene glycol, and glycerol were estimated at six flow rates 9, 11, 13, 21, 41, and 47 mL/sec. The mass (mg) of the chemical transferred from liquid to aerosol during aerosolization is shown in their respective flow rate bars. The averaged transfer efficiency and mass (mg) transferred are shown for nicotine, menthol, WS-23, propylene glycol, and glycerol at the six flow rates. * = $p < 0.05$; ** = $p < 0.01$; *** = $p < 0.001$; **** = $p < 0.0001$.

184x278mm (300 x 300 DPI)




Figure 2: Mass Transfer and Percent Efficiency of Nicotine, Menthol, WS-23 and the Solvents in JUUL™ "Menthol" Pods Plotted at Various Flow Rates. (A-E) The transfer efficiency of nicotine, menthol, WS-23, propylene glycol, and glycerol were plotted separately at various flow rates 9, 11, 13, 21, 41, and 47 mL/sec. The mass (mg) of the chemical transferred from liquid to aerosol during aerosolization is shown in their respective flow rate bars. * = $p < 0.05$; ** = $p < 0.01$; *** = $p < 0.001$.

194x262mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 3: Maximal and Actual Exposure for Each Dominant Chemical. The estimated maximal and actual exposures (A-D) and their averages \pm SD were calculated for nicotine, menthol, PG, and G as described in the Materials & Methods. Light Red = maximal exposure; Red = actual exposure.

205x128mm (300 x 300 DPI)







Figure 4: Total Exhale Quantified for Each Participant During Day 2 Session. (A) The total exhale (mg) for nicotine, menthol, and WS-23 quantified for each user. (B) The total exhale (mg) for propylene glycol and glycerol quantified for each user.

216x229mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 5: Mass and Percent Retained Calculated for Nicotine, Menthol, PG, and G at 21 mL/sec for Each User. The estimated mass delivered (A, C, E, G) and percent retention (B, D, F, H) was computed by calculating the amount of nicotine, menthol, PG, and G consumed and subtracting from this from the amount of nicotine, menthol, PG, and G exhaled.

213x259mm (300 x 300 DPI)



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 6: Acute Symptoms Observed for Users During Exhale Session. (A-B) The most reported symptoms before, during, and after vaping are shown along with the average number of symptoms reported during Day 1 and 2 sessions. (C) Total exposure calculated for vapers from all four chemicals. (D) The correlation between the number of symptoms (Y-axis) and the total chemical mass retained (X-axis).

203x132mm (300 x 300 DPI)



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60





Figure 7: Total ECEAR Concentrations for Each Participant During Day 1 Session. (A) The total ECEAR mass (mg) in the acrylic box for nicotine and menthol for each user. (B) The total ECEAR mass (mg) in the acrylic box for PG and G for each user.

200x248mm (300 x 300 DPI)



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 8: Summary of Major Results.

338x190mm (96 x 96 DPI)



**Exposure, Retention, Exhalation, Symptoms, and Environmental Accumulation of
Chemicals During JUUL™ Vaping**

My Hua†,‡, Wentai Luo§, Careen Khachatoorian‡, Kevin J. McWhirter§, Sara Leung‡, Teresa
Martinez‡, and Prue Talbot*†,‡

†Environmental Toxicology Graduate Program University of California, Riverside, Riverside, CA,
92521, United States,

‡Department of Molecular, Cell and Systems Biology, University of California, Riverside,
Riverside, CA, 92521, United States,

§Department of Civil and Environmental Engineering, Portland State University, Portland, OR,
97201, United States

Address correspondence to: Prue Talbot, Department of Molecular, Cell and Systems
Biology, University of California, Riverside, 600 University Dr. Riverside, CA 92521, USA

Telephone: 951-827-3768.

E-mail: talbot@ucr.edu

Table of Contents

Supplementary Figure 1: Overview of the Workflow for the Study.

Supplementary Figure 2: Concentration and Percent Composition of Dominant Chemicals in JUUL™ “Menthol” E-Liquid. (A) The chemical concentrations (mg/mL) for nicotine, menthol, propylene glycol, glycerol, and their combined total are shown. (B) The percentages of nicotine, menthol, propylene glycol, and glycerol in JUUL™ “Menthol” e-liquid. Benzoic acid is not included in the diagram.

Supplementary Figure 3: The Total E-Liquid Weight Consumed (mg) for All Users Across the Two Day Sessions.

Supplementary Figure 4: Puff Duration and Total Puffs Seconds. (A) The puff duration (mean \pm SD) and puff count for each user was recorded across both study sessions (Day 1 and Day 2). The insert shows the average puff duration for one participant on three different days and the average over three days. (B) The total puffs seconds (TPS) was calculated for each user across both study days. The TPS was calculated by multiplying the users’ total puff count times the puff duration.

Supplementary Figure 5: The Total Exhale (mg) for Non-Dominant Chemicals (Benzaldehyde, Triacetin, and Acetophenone) for Each User.

Supplementary Figure 6: The Total ECEAR Mass (mg) for Non-Dominant Chemicals (Benzyl Alcohol, Hexanol, Triacetin, Acetophenone, Isoamyl Isovalerate, and p-Tolualdehyde).


Supplementary Table 1: List of Abbreviations and Terms Commonly Used In the Paper.

Supplementary Table 2: Flavor Chemicals (< 1 mg/mL) in Unvaped and Vaped JUUL™ Menthol Pod Fluid Averaged Across Two Sessions.

Supplementary Table 3: Total Mass and Percent Retained for Nicotine, Menthol, Propylene Glycol, and Glycerol Calculated at Various Flow Rates (9, 11, 13, 41, and 47 mL/sec).


Supplementary Table 4. Dominant Chemical Exposures for JUUL™ Users and Estimated Cigarette Equivalency Based on Nicotine

References




Supplementary Figure 1: Overview of the Workflow for the Study.


Dominant Chemical Concentrations in Unvaped JUUL Pods



Average Percent Composition of JUUL Menthol Pods




Supplementary Figure 2: Concentration and Percent Composition of Dominant Chemicals in JUUL™ “Menthol” E-Liquid. (A) The chemical concentrations (mg/mL) for nicotine, menthol, propylene glycol, glycerol, and their combined total are shown. (B) The percentages of nicotine, menthol, propylene glycol, and glycerol in JUUL™ “Menthol” e-liquid. Benzoic acid is not included in the diagram.




Supplementary Figure 3: The Total E-Liquid Weight Consumed (mg) for All Users Across the Two Day Sessions.

Puff Duration and Number for Days 1 and 2 Study Sessions




Total Puff Seconds for Participants




Supplementary Figure 4: Puff Duration and Total Puffs Seconds. (A) The puff duration (mean \pm SD) and puff count for each user was recorded across both study sessions (Day 1 and Day 2). The insert shows the average puff duration for one participant on three different days and the average over three days. (B) The total puffs seconds (TPS) was calculated for each user across both study days. The TPS was calculated by multiplying the users' total puff count times the puff duration.


Total Benzaldehyde Exhaled by Study Participants









Total Triacetin Exhaled by Study Participants



Total Acetophenone Exhaled by Study Participants



Supplementary Figure 5: The Total Exhale (mg) for Non-Dominant Chemicals (Benzaldehyde, Triacetin, and Acetophenone) for Each User.



Supplementary Figure 6: The Total ECEAR Mass (mg) for Non-Dominant Chemicals (Benzyl Alcohol, Hexanol, Triacetin, Acetophenone, Isoamyl Isovalerate, and p-Tolualdehyde).

Supplementary Table 1. Abbreviations and Terms

Abbreviations

ANOVA = analysis of variance

EC = electronic cigarette

ECEAR = electronic cigarette exhaled residue

FDA = Food and Drug Administration

GC/MS = gas chromatography/mass spectrometry

G = glycerol

IPA = isopropyl alcohol

LOQ = limit of quantification

PG = propylene glycol

THS = thirdhand smoke

TSNAs = tobacco specific nitrosamines

TPS = total puffs seconds

WS-23 = 2-Isopropyl-N,2,3-trimethylbutyramide (a synthetic coolant found in some e-liquids)

Terms

Actual Exposure: the dose users receive that takes into account the transfer efficiency (%) for each chemical.

Dominant Chemicals: chemicals that were quantified in JUUL™ Menthol pod fluid and had concentrations > 1 mg/mL (nicotine, menthol, PG, G).

Mass transfer: the mass of a chemical transferred during aerosolization.

Mass Retained: the mass of a chemical retained by e-cigarette users after exhaling.

Maximal Exposure: the dose calculated from the total pod liquid (mL) consumed by users and multiplied by the concentration (µg/mL) of the chemical. It does not take into account the transfer efficiency (%) for each chemical.

Non-Dominant Chemicals: chemicals that were quantified in JUUL™ Menthol pod fluid and had concentrations < 1 mg/mL.

Percent Retention: the percentage of a chemical retained after vaping.

Transfer efficiency: the percent of chemical transferred from refill fluid to aerosol during vaping.

Supplementary Table 2. Flavor Chemicals Detected (≤ 1 mg/mL) in Unvaped and Vaped JUUL™ “Menthol” Pods¹

	WS-23	Benzyl Alcohol	Hydroxyacetone	β -Demascone	p-Menthone	Neomenthol	Caffeine	Isopulegol
Unvaped Pods	106.55	75.5	22.6	19.7	17.9	18.7	11.6	22.65
JD	101.85	65.7	30.45	3.9	3.25	2.1	11.45	
BN	100.3	63.8	29.85	3.55	3.3	1.8	11	
VN	97.25	62.25	29	4.55	4.3	2.45	11.1	
JE	104.1	66.85	30.05	4.65	4.35	2.45	12.05	
BO	95.25	60.3	30.4	3.85	2.85	1.65	11.05	
LO	105	66.75	30.3	4	3.2	2.1	12.7	
AS	111.85	67.85	36.05	6	4.85	2.6	11.3	
MB	100.75	64.90	33.15	4.5	3.4	2.2	11.7	
JL	108.35	67.35	32.75	4.9	5.1	2.8	11.65	
MN	118.05	70.15	36.2	6.25	5.3	2.6	11.25	
BL	113.05	67	31.9	7.05	6.95	3.05	11.1	
JE	102.1	65.10	33.05	3.45	3.3	2.2	11.95	

¹Only chemicals greater than the limit of quantification (>10 μ g/mL) are shown.

Supplementary Table 3. Total Mass and Percent Retained for Nicotine, Menthol, Propylene Glycol, and Glycerol Calculated at Various Flow Rates (9, 11, 13, 41, and 47 mL/sec)

Mass or Percent Retained (Flow Rate) ¹	AS	MN	JL	JD	JE	MB	BO	BN	LO	BL	VN	Average ± SD
N-MR (mg) (9)	6.4	5.1	3.2	2.9	2.9	2.1	1.4	1.4	1.1	0	0.3	2.4 ± 2.0
N-PR (%) (9)	100	100	100	100	99.8	100	100	99.9	99.8	0	86.8	87.1 ± 38.5
N-MR (mg) (11) ²	7.7	6.2	3.8	3.5	3.4	2.5	1.7	1.6	1.3	0	0.4	3.0 ± 2.4
N-PR (%) (11)	100	100	100	100	99.9	100	100	99.9	99.8	0	89.1	89.3 ± 32
N-MR (mg) (13)	9.4	7.5	4.6	4.2	4.2	3.1	2.0	2.0	1.5	0.1	0.5	3.6 ± 2.9
N-PR (%) (13)	100	100	100	100	99.9	100	100	100	100	12	91	91.1 ± 26.4
N-MR (mg) (41)	7.5	6.0	3.7	3.4	3.3	2.5	1.6	1.6	1.2	0	0.4	2.8 ± 2.3
N-PR (%) (41)	100	100	100	100	99.9	100	100	99.9	99.8	0	88.7	89 ± 32.9
N-MR (mg) (47)	7.9	6.4	3.9	3.6	3.5	2.6	1.7	1.7	1.3	0	0.4	3.0 ± 2.4
N-PR (%) (47)	100	100	100	100	99.9	100	100	99.9	99.8	0	89.4	89.6 ± 31.1
M-MR (mg) (9)	0.9	0.8	0.5	0.4	0.4	0.3	0.2	0.2	0.2	0	0.04	0.4 ± 0.3
M-PR (%) (9)	93.7	99.1	99.2	91.8	93.9	98	100	98.6	95	0	80.2	86.3 ± 29.4
M-MR (mg) (11)	1.1	0.9	0.6	0.5	0.5	0.4	0.2	0.2	0.2	0.02	0.05	0.4 ± 0.3
M-PR (%) (11)	94.5	99.2	99.3	92.9	94.7	98.3	100	98.8	95.6	12.2	82.8	88 ± 25.6
M-MR (mg) (13)	1.3	1.1	0.7	0.6	0.6	0.5	0.3	0.3	0.2	0.04	0.07	0.5 ± 0.4
M-PR (%) (13)	95.5	99.4	99.4	94.1	95.6	98.6	100	99	96.4	27.6	85.8	90.1 ± 21.1
M-MR (mg) (41)	1.2	1.0	0.6	0.5	0.5	0.4	0.3	0.3	0.2	0.03	0.06	0.5 ± 0.4
M-PR (%) (41)	95	99.3	99.3	93.6	95.3	98.5	100	98.9	96.1	20.7	84.4	89.2 ± 23.1
M-MR (mg) (47)	1.4	1.1	0.7	0.6	0.6	0.5	0.3	0.3	0.2	0.04	0.07	0.5 ± 0.4
M-PR (%) (47)	95.5	99.4	99.4	94.2	95.7	98.6	100	99	96.5	28.9	86	90.3 ± 20.8
PG-MR (mg) (9)	29.2	23.4	14.4	13.2	13	9.6	6.3	6.2	4.8	3.2	1.6	11.3 ± 8.6
PG-PR (%) (9)	100	100	100	100	100	100	100	100	100	99.9	100	100 ± 0.03
PG-MR (mg) (11)	38.9	31.2	19.3	17.6	17.3	12.7	8.4	8.2	6.4	4.2	2.2	15.1 ± 11.4
PG-PR (%) (11)	100	100	100	100	100	100	100	100	100	99.9	100	100 ± 0.03
PG-MR (mg) (13)	38.9	31.2	19.3	17.6	17.3	12.7	8.4	8.2	6.4	4.2	2.2	15.1 ± 11.4
PG-PR (%) (13)	100	100	100	100	100	100	100	100	100	99.9	100	100 ± 0.03
PG-MR (mg) (41)	48.6	39	24.1	22	21.6	15.9	10.5	10.3	8	5.3	2.7	18.9 ± 14.3
PG-PR (%) (41)	100	100	100	100	100	100	100	100	100	99.9	100	100 ± 0.02
PG-MR (mg) (47)	48.6	39	24.1	22	21.6	15.9	10.5	10.3	8	5.3	2.7	18.9 ± 14.3
PG-PR (%) (47)	100	100	100	100	100	100	100	100	100	99.9	100	100 ± 0.02
G-MR (mg) (9)	52.4	42	26	23.7	23.3	17.2	11.4	11.1	8.6	5.7	2.9	20.4 ± 15.4
G-PR (%) (9)	100	100	100	100	100	100	100	100	100	99.8	99.9	100 ± 0.06
G-MR (mg) (11)	69.5	55.8	34.5	31.5	30.9	22.8	15.1	14.7	11.4	7.6	3.9	27.1 ± 20.5
G-PR (%) (11)	100	100	100	100	100	100	100	100	100	99.8	100	100 ± 0.05
G-MR (mg) (13)	80.9	64.9	40.1	36.7	36	26.5	17.6	17.1	13.3	8.8	4.5	31.5 ± 23.8
G-PR (%) (13)	100	100	100	100	100	100	100	100	100	99.9	100	100 ± 0.04

G-MR (mg) (41)	112.8	90.5	55.9	51.1	50.2	37	24.5	23.9	18.5	12.3	6.3	43.9 ± 33.2
G-PR (%) (41)	100	100	100	100	100	100	100	100	100	100	100	100 ± 0.03
G-MR (mg) (47)	118.5	95.1	58.7	53.7	52.7	38.8	25.7	25.1	19.5	13	6.6	46.1 ± 34.9
G-PR (%) (47)	100	100	100	100	100	100	100	100	100	99.9	100	100 ± 0.03

¹N = nicotine; M = menthol; PG = propylene glycol; G = glycerol; MR = mass retained; PR = percent retained.

²Numbers in parentheses indicate the flow rate for the calculation.

Supplementary Table 4. Dominant Chemical Exposures for JUUL™ Users and Estimated Cigarette Equivalency Based on Nicotine¹

User	Number of Puffs Taken Per Session	Nicotine Retained (mg) in Single Puff (sp) ² , Single Session (ss) ³ , and Whole Day (wd) ⁴	Menthol Retained (mg) in Single Puff (sp), Single Session, and Whole Day (wd)	PG Retained (mg) in Single Puff (sp), Single Session (ss), and Whole Day (wd)	G Retained (mg) in Single Puff (sp), Single Session (ss), and Whole Day (wd)	Total Solvent Retained (mg) in Single Puff (sp), Single Session (ss), and Whole Day (wd)	Nicotine Retained Comparison to Smokers (1.1 mg/Cigarette) ^{5,6} in a Single Session and Whole Day (22 mg for ppd) ⁷
AS	26	0.3 (sp); 8.7 (ss); 46.2 (wd)	0.05 (sp); 1.4 (ss); 7.5 (wd)	1.9 (sp); 48.6 (ss); 261.6 (wd)	5.3 (sp); 136.7 (ss); 736.4 (wd)	7.1 (sp); 185.3 (ss); 997.9 (wd)	~8 cigarettes (ss); ~2.1 ppd (wd)
JD	16	0.3 (sp); 3.9 (ss); 34.5 (wd)	0.04 (sp); 0.6 (ss); 5.5 (wd)	1.4 (sp); 22 (ss); 192.6 (wd)	3.9 (sp); 62 (ss); 542.1 (wd)	5.2 (sp); 84 (ss); 734.7 (wd)	~3.6 cigarettes; ~1.6 ppd (wd)
MN	25	0.3 (sp); 7.0 (ss); 39.1 (wd)	0.05 (sp); 1.2 (ss); 6.5 (wd)	1.6 (sp); 39 (ss); 218.2 (wd)	4.4 (sp); 109.7 (ss); 614.2 (wd)	5.9 (sp); 148.6 (ss); 832.4 (wd)	~6.4 cigarettes; ~1.8 ppd (wd)
JL	21	0.2 (sp); 4.3 (ss); 28.8 (wd)	0.03 (sp); 0.7 (ss); 4.8 (wd)	1.1 (sp); 24.1 (ss); 160.5 (wd)	3.2 (sp); 67.8 (ss); 451.9 (wd)	4.4 (sp); 91.9 (ss); 612.4 (wd)	~4 cigarettes (ss); ~1.3 ppd (wd)
JE	20	0.2 (sp); 3.9 (ss); 27.1 (wd)	0.03 (sp); 0.6 (ss); 4.4 (wd)	1.1 (sp); 21.6 (ss); 151.2 (wd)	3 (sp); 60.8 (ss); 425.9 (wd)	4.1 (sp); 82.5 (ss); 577.2 (wd)	~3.5 cigarettes; ~1.2 ppd (wd)
MB	26	0.1 (sp); 2.9 (ss); 15.4 (wd)	0.02 (sp); 0.5 (ss); 2.5 (wd)	0.6 (sp); 15.9 (ss); 85.7 (wd)	1.7 (sp); 44.80 (ss); 241.2 (wd)	2.3 (sp); 60.7 (ss); 327 (wd)	~2.6 cigarettes (ss); ~0.7 ppd (wd)
BO	22	0.09 (sp); 1.9 (ss); 12.0 (wd)	0.01 (sp); 0.3 (ss); 2.0 (wd)	0.5 (sp); 10.5 (ss); 67.1 (wd)	1.3 (sp); 29.7 (ss); 188.8 (wd)	1.8 (sp); 40.2 (ss); 255.8 (wd)	~1.7 cigarettes; ~0.5 ppd (wd)
BN	21	0.09 (sp); 1.8 (ss); 12.3 (wd)	0.01 (sp); 0.3 (ss); 2.0 (wd)	0.5 (sp); 10.3 (ss); 68.5 (wd)	1.4 (sp); 28.94 (ss); 192.9 (wd)	1.9 (sp); 39.2 (ss); 261.5 (wd)	~1.7 cigarettes; ~0.6 ppd (wd)
LO	36	0.04 (sp); 1.4 (ss); 5.5 (wd)	0.006 (sp); 0.2 (ss); 0.9 (wd)	0.2 (sp); 8.0 (ss); 31 (wd)	0.6 (sp); 22.5 (ss); 87.3 (wd)	0.8 (sp); 30.4 (ss); 118.4 (wd)	~1.3 cigarettes; ~0.3 ppd (wd)
VN	11	0.04 (sp); 0.4 (ss); 5.6 (wd)	0.006 (sp); 0.07 (ss); 0.9 (wd)	0.2 (sp); 2.7 (ss); 34.3 (wd)	0.7 (sp); 7.6 (ss); 96.8 (wd)	0.9 (sp); 10.3 (ss); 131.2 (wd)	<1 cigarette; ~0.3 ppd (wd)
BL	23	0.002 (sp); 0.05 (ss); 0.3 (wd)	0.002 (sp); 0.05 (ss); 0.3 (wd)	0.2 (sp); 5.3 (ss); 32.3 (wd)	0.6 (sp); 14.9 (ss); 90.9 (wd)	0.9 (sp); 20.2 (ss); 123.2 (wd)	<1 cigarette; ~0.01 ppd (wd)

¹ = JUUL™ calculations were based on 21 mL/sec flow rate

² = Single puffs (sp) data were calculated from total actual exposure data divided by the total number of puffs users took in a session.

³ = Single session (ss) data were estimated by multiplying the total number of puffs recorded for each user during a session by the single puff data.

⁴ = Whole day (wd) exposures were calculated by multiplying the single puff data by 140 puffs/day. 140 puffs/day was chosen based on previously reported data¹.

⁵ = To obtain the estimated cigarette equivalency, the amount of nicotine delivered by a JUUL™ “Menthol” EC in a 20-minute session was divided by the amount delivered by one Marlboro Red filtered cigarette (1.1 mg/cigarette)².

⁶ = The estimated cigarette equivalency for a single session was calculated by dividing the users’ individual single session nicotine data by 1.1 mg.

⁷ = The estimated cigarette equivalency for a whole day was calculated by dividing the whole day exposure data by nicotine delivered in a single cigarette (1.1 mg) or pack of cigarettes (22 mg). If the users’ whole day nicotine exposure was \geq 22mg it was divided by 22 mg.

References

1. Dautzenberg B, Bricard D. Real-time characterization of e-cigarettes use: the 1 million puffs study. *J. Addict. Res. Ther.* 2015;6(229.10):4172.
2. Federal Trade Commission. "Tar," nicotine, and carbon monoxide of the smoke of 1294 varieties of domestic cigarettes for the year 1998, 2000.